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Abstract: Research in Alzheimer’s disease is increasing worldwide because of its dramatic impact on society 
and the healthcare costs it causes. Although many potential formulations are continuously evaluated, at present 
most of the available therapies are only symptomatic treatments. However, a number of therapeutic targets 
have been defined mainly related to two pathological hallmarks of Alzheimer’s disease: first, the accumulation of amyloid 
β peptide aggregates in the central nervous system (CNS) and, second, the presence of neurofibrillary tangles inside the 
neuronal cells. The therapeutic targets are located in the CNS, which limits the efficacy of drugs systemically 
administered: the blood brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the 
systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.  
In recent years nanoparticles have been used as drug carriers to enhance the solubility, circulation time and bioavailability 
of all kind of drugs, also applied to Alzheimer’s disease treatment. Moreover, nanoparticles have also been designed to 
cross the BBB or to use alternative administration routes to overcome it (i.e. intranasal administration), thus allowing the 
release of the drug cargo in CNS. 
Herein the application of nanoparticles to enhance the targeting of drugs to the brain for Alzheimer treatment is reviewed. 
In most cases, the multivalency of nanoparticles in terms of the functionalization of their surface is reported to be crucial 
for the successful delivery of the drug. The carrier should be grafted with specific moieties to overpass the BBB and to 
direct an active molecule to a particular molecular target in the brain. In this sense nanotechnology-based approaches 
would help to avoid invasive administration and to increase the efficacy of less invasive treatments. 
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1. INTRODUCTION
 Alzheimer’s disease (AD) has been gaining more and 
more attention in the last decade due to the registered 
increase of dementia cases and the lack of success in finding 
effective treatments. No successful prevention strategy or 
therapy has been found up to now leading to AD ranking as 
6th cause of death in the United States [1, 2]. 
 Dementia has recently been called ‘twenty- first century 
plague’ and considered as public health priority. World 
Health Organization 2012 report on dementia estimated that 
there were 35.6 million people living with dementia 
worldwide that year [3], while according to World 
Alzheimer Report (Alzheimer’s Disease International) the 
estimation in 2015 had increased to 46.8 million people [4]. 
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 AD is the most common cause of dementia. It affects 
prevalently people older than 65 years, since younger onset 
dementia is a rare condition accounting for approximately 
5% of all cases. In the world there are currently nearly 900 
million people over 65 years old and due to the increase of 
the world population the frequency of dementia cases is 
expected to almost double by 2030. Neither healthcare nor 
financial systems are prepared to face the magnitude of the 
situation [4]. 
 Alzheimer’s disease also affects familiar and social 
relationships with a devastating impact for caregivers, since 
they often suffer high emotional stress and depression that 
supposes significant additional health care costs [5]. 
 About the geographic distribution of AD, in World 
Alzheimer Report (ADI) for 2015 it was estimated that 80% 
of all people with dementia live in the world’s 20 richest 
countries [4]. According to statistics, in 2015, East Asia is 
the world region with the largest amount of people living 
with dementia (9.8 million), followed by Western Europe 
(7.4 million). These regions are closely followed by South 
Asia with 5.1 million and North America with 4.8 million. 
Taking into account the number of the statistics addressed, 
the need for effective therapies is dramatically evident.  
 AD is a heterogenic, complex disorder characterized by a 
multiple impairment of physiological and cellular functions 
caused by genetic, epigenetic, and environmental factors. In 
1906, Alois Alzheimer described for the first time distinctive 
plaques and neurofibrillary tangles in the brain of a 50-year-
old woman presenting severe cognitive dysfunctions [6]. A 
more in-depth description of Alzheimer’s disease and the 
distinction from dementia deriving from cerebrovascular 
anomalies was reported by Roth later in 1955 [7]. Aalten and 
coworkers identified four different sub-syndromes of 
neuropsychiatric symptoms of AD: hyperactivity 
(aggression, disinhibition, irritability, aberrant motor 
behavior and euphoria), psychosis (delusion, hallucination 
and sleep disorder), affectivity (depression and anxiety) and 
apathy (apathy and appetite disorder) [8]. The variability of 
neuropsychiatric symptoms has been also revised by Zhao 
and colleagues in a very recent statistical analysis [9]. 
 Alzheimer’s diagnosis is currently dependent in a large 
part on cognitive and functional assessments. In the first 
phase of the illness, mild cognitive impairment and short-
term and spatial memory deficits are the only symptoms, 
therefore most of the time they can be underestimated and an 
early diagnosis is not possible. AD diagnosis is especially 
difficult in the case of early-onset AD (EOAD), when the 
disease develops at an age under 65 years old. In this case 
AD is very often overlooked by health professionals due to 
its rare condition, about 5% of all AD cases. Symptoms may 
be incorrectly attributed to stress or there may be conflicting 
diagnoses from different health care professionals. 
 EOAD is also referred as familial AD as it is caused by 
very rare, penetrant and deterministic mutations in genes 
coding for amyloid precursor protein (APP); for presenilins 1 
and 2 (PSN1 and PSN2), which are basic components of the 
amyloid beta (Aβ) cleaving γ-secretases; and, for alpha-2 
macroglobulin [10, 11]. On the other hand, late-onset AD 
(LOAD) is age-related (≥65 years) and associated to diverse 
risk factors including epigenetic alterations, environment, 
ageing and genetics [12, 13]. In this respect, one of the best 
established risk factors in LOAD is the presence of ε4 
isoform of Aβ transporter apolipoprotein E (ApoE) [14]. 
Individuals carrying both alleles of APOE ε4 gene have a 
50 % greater probability of developing the disease. 
 Interestingly the deterministic and risk genes involved in 
AD are mostly related to the production and transport of Aβ 
peptides. Consistently, one of the two major pathological 
hallmarks of AD is the accumulation of Aβ peptides in the 
brain parenchyma forming amyloid plaques outside and 
around neurons, and in the walls of small brain arteries. The 
other is the formation of intracellular neurofibrillary tangles, 
pathological aggregates of hyperphosphorylated 
microtubule-associated tau protein [15-18]. Besides these 
lesions, a strong oxidative stress and a pathological 
dysfunction associated to brain blood barrier (BBB) 
permeability often concur to generate synaptic damages and 
neuronal loss. 
 The complete molecular network contributing to the 
neuronal and synaptic loss behind the clinical features of AD 
appears intricate and has not been elucidated yet [19]. Long 
standing amyloid cascade hypothesis [20, 21] situates the 
accumulation of Aβ peptides as the initial factor for AD 
which would unleash the hyperphosphorylation of tau 
proteins and finally, neuronal dysfunction and death. That 
hypothesis is currently under question, but clearly those two 
pathological lesions play an important role in AD along with 
other alterations [19, 22]. Following we will separately 
describe the main issues related to AD along with the 
potential targets for AD therapies. 
Figure 1. APP (a) can be cleaved by α-secretase within 
the amyloid sequences (blue) (b), or by β-site APP cleaving 
enzyme (BACE), which cleaves APP in the extracellular 
space at the β-site (c). Overall, these enzymatic reactions 
generate two large soluble ectodomains, termed sAPPα and 
sAPPβ, respectively. sAPPα is considered the precursor of 
the so-called nonamyloidogenic pathway, while the sAPPβ 
concurs to initiate the amyloidogenic one (pathogenic). In 
particular, subsequent processing of the carboxy-terminal 
fragments (CTFs) of sAPPβ by γ-secretase results in the 
production of Aβ and the APP intracellular domain (AICD). 
γ-secretase-mediated cleavage is slightly imprecise and 
generates C-terminal heterogeneity of Aβ peptide lengths 
[23]. 
2. PATHOLOGICAL HALLMARKS OF AD
2.1. Deposition of the Aβ peptides 
 Aβ peptides are highly fibrillogenic peptides, which give 
rise to oligomeric species and plaques that accumulate in the 
brain of patients of AD and of other cognitive disorders such 
as Down’s syndrome. From all the forms of aggregation of 
Aβ peptides, the soluble oligomers seem to be the most toxic 
ones due to their ability for triggering pathological responses 
in cells by interacting with their membranes.  
 Physiologically speaking, Aβ are secreted peptides, 
prevalently anabolized and catabolized in the brain at 
relatively low levels. They originate from a sequential 
cleavage of amyloid precursor protein (APP) mediated by 
membrane-bound endoproteases, namely β- and γ-secretases 
[23-25]. APP is a member of a single-pass transmembrane 
protein family, presenting a large extracellular domain and a 
short cytoplasmic tail (Figure 1). APP biological function is 
still object of debate and remains largely undefined. 
However, the most likely hypotheses suggest that APP may 
play a role in cell and synaptic adhesion, synaptic pruning, 
cell signaling and apoptosis [26]. Conversely, the APP 
metabolism mediated by secretases, the fate of APP-derived 
fragments and the deposition of Aβ peptides are much better 
understood. Basically two distinct pathways (amyloidogenic 
and non-amyloidogenic) have been described as 
schematically reported in Figure 1 [23-25]. 
 The amyloidogenic pathway originates from the 
consecutive action of beta-site APP cleaving enzyme (β-
secretase, BACE) and γ-secretase. γ -secretase catalyses last 
cleavages and generates the C-terminus of Aβ peptides. Its 
action produces a large repertoire of fragments with diverse 
tendency to form deposits [23]. Among the Aβ species, the 
40-residue (Aβ40) is the most abundant peptide (~80-90%), 
followed by 42-residue fragment (Aβ42, ~5-10%) and even 
longer variants, less abundant, but still pathogenic. The 
Aβ42 species is more hydrophobic and fibrillogenic than 
Aβ40, thus contributing prominently to extracellular plaque 
formation. From the structural point of view, γ-secretase is a 
multiprotein complex with a catalytic core consisting of 
presenilin 1 (PS1) or presenilin 2 (PS2), whose coding genes 
are involved in EOAD.  
 On the basis of current knowledge, it appears clear that 
both β− and γ-secretases are key players in Aβ production 
and deposition, suggesting that regulating their enzymatic 
activities in the brain may be beneficial against AD. Not 
surprisingly, BACE and γ-secretases have become object of 
an intense research aimed at reducing Aβ production [27]. 
Aβ peptides accumulation and subsequent aggregation are 
consequences of an imbalance between their production, and 
their clearance from the brain [28]. Production of Aβ 
peptides has been treated above. Their clearance occurs 
through BBB and also by cellular mechanisms. Influx and 
efflux of Aβ are receptor-mediated and their dynamics are 
described below, in the frame of the dysfunctions of BBB 
associated to AD. 
 Likewise receptor dynamics, Aβ transport and removal 
matter. Apolipoprotein E (ApoE) is a key protein involved in 
Aβ clearance [29]. ApoE mediates the transport of lipids, 
cholesterol and other hydrophobic molecules, including 
amyloid β (Aβ). In 1991, Namba and colleagues reported the 
first evidences that ApoE was co-deposited in senile plaques 
in the brains of AD patients [30]. Genetic findings confirmed 
that the highly polymorphic ApoE gene is an important risk 
factor in AD [14, 31].  
How and to what extent ApoE isoforms differentially 
contribute to Aβ aggregation, transport and clearance in the 
brain is still debated. In fact, data from in vitro and in vivo 
studies as well as those coming from clinical observations 
are tremendously conflicting.  Recent findings show that 
ApoE4 is less efficient in Aβ clearance than is ApoE3 in 
transgenic mouse models of Aβ-amyloidosis [32]. ApoE 
might control, in an isoform-specific way, Aβ removal from 
the brain to the systemic circulation through the blood–brain 
barrier [29]. All these scientific evidences suggest that 
developing treatments directed toward ApoE could represent 
an interesting therapeutic strategy against AD [33]. 
 Finally, increasing evidences strongly support the 
hypothesis that Aβ accumulation may be also debited to 
dysfunction in the cellular mechanisms for Aβ clearance. In 
‘90s many scientific findings demonstrated the relationship 
between lysosomal dysfunction and morphology in AD, 
suggesting that lysosomal defects may be the earliest 
histological change in this pathology [34].  
 The role of transcription factor TFEB in AD has been 
recently investigated as well. TFEB is the master regulator of 
lysosomal biogenesis [35]. Viral gene transfer of TFEB in 
neurons of APP/PS1 mouse model of AD accelerated 
lysosomal degradation of endocytosed APP, which reduced 
the steady-state levels of APP and in turn decreased both the 
interstitial fluid Aβ levels and amyloid deposits [36]. 
2.2. Neurofibrillary tangle formation 
 The second pathological abnormality in AD brain is the 
presence of intracellular neurofibrillary tangles (NFTs) 
formed by filaments of hyperphosphorylated microtubule-
associated protein tau (MAPT), which impair severely the 
microtubule functions and lead to the collapse of 
cytoskeleton. Interestingly, tau behaves as a natively 
unfolded protein or intrinsically disordered protein, lacking 
significant amounts of secondary structure in the longest 
isoform. This means that this protein is highly flexible and 
may have variable conformations [37]. Tau protein consists 
of an N-terminal acidic region followed by a proline-rich 
region and a C-terminal basic portion. Tau anchors to the 
microtubule through a repeated domain at C-terminal, while 
the N-terminal part projects from the microtubule surface 
creating an active interface for further interactions with other 
cytoskeletal elements and neuronal plasma membrane 
components (Figure 2) [38].  
 Genetic evidences show that mutations in tau gene in 
familial frontotemporal dementia and Parkinson linked to 
chromosome 17 (FTDP-17) cause neurodegeneration and 
dementia [39]. Interestingly, the FTDP-17 mutations appear 
to alter conformation of tau protein making it more prone for 
subsequent phosphorylation mediated by brain protein 
kinases [40]. 
 The abnormal hyperphosphorylation of tau is recurrent in 
AD and other related neurodegenerative disorders 
(taupathies). When tau becomes hyperphosphorylated 
dissociates from the microtubules and accumulates as 
insoluble fibrils, finally forming NFTs (Figure 2). 
The presence of aberrant tau proteins could affect the 
function of microtubules [41]. In neurons, microtubules are 
involved in cell architecture and form dynamic structures 
along which organelles and functional information are 
shuttled. Therefore, cytoskeleton dysfunction in neuronal 
cells definitely prejudices their normal functions. At the 
onset of AD, intraneuronal NFTs are confined to distinct 
brain districts. Afterwards, spreading effects have been 
largely correlated to disease progression, suggesting that 
NFTs contribute to synaptic deficits and irreversible 
neuronal loss in AD. As tau cytoplasmic levels notably 
increase after hyperphosphorylation, it occurs that tau also 
aberrantly interacts with a plethora of cellular proteins, 
further perturbing cell homeostasis. Aberrant 
hyperphosphorylation can be debited to abnormal activity of 
tau kinases and phosphatases as well. Glycogen synthase 
kinase 3β (GSK-3β or Tau kinase 1) cyclin-dependent kinase 
5 (cdk5), cAMP-dependent protein kinase (PKA), and 
calcium/calmodulin-dependent kinase II (CaMK-II) are the 
most important kinases involved in tau phosphorylation [42, 
43]. 
Figure 2. Tau is a microtubule-associated protein able to 
bind the interface between tubulin hetero-dimers promoting 
microtubule assembly and stabilization in the brain. 
Hyperphosphorilation of Tau inhibits its binding to 
microtubules and induces self-aggregation of tau into 
filaments. Neurofibrillary tangles (NFTs) are widely 
associated to neurodegeneration. 
2.3. Dysfunction of the blood brain barrier 
 A rich network of blood vessels nourishes the brain. 
Therein, the circulating blood is separated from the 
extracellular fluid in the central nervous system (CNS) by a 
highly selectively permeable barrier, the blood brain barrier 
(BBB), which is formed by brain endothelial cells connected 
by tight junctions. The main function of BBB is the selective 
control of fluid and biomolecule exchange between the CNS 
and the systemic circulation. The tight packing of brain 
endothelial cells restricts the diffusion of large and/or 
hydrophilic entities into the CNS while allowing the 
diffusion of small and/or lipophilic substances. Other 
substances that are needed by CNS are allowed through the 
BBB by active receptor-mediated transport [44]. 
 Many evidences relate neurodegenerative diseases with 
alterations of the normal functionality of the BBB or its 
integrity. Changes in a number of transport pathways could 
be involved, including transcellular transport (receptor-
mediated and adsorptive transcytosis) [45]. In particular, in 
the case of transcytosis transport, only the transport through 
the basal or apical membrane could be affected, determining 
a condition of imbalance. In Alzheimer’s disease affected 
brains, some important transport carriers or receptors show 
physiopathological changes. In particular, the neurovascular 
hypothesis has been proposed as a mechanism of pathogenic 
cascades for AD [17, 46]. Up to now, it is still unclear 
whether the neurovascular alterations reported in AD 
patients are the cause or the effect in the disease process. 
However it is proven that there is a relationship between 
neurovascular changes and disease progression associated 
with neuronal dysfunction [17]. 
 Impaired vascular clearance of Aβ across the BBB 
increases its capillary deposition and the formation of 
amyloid lesions [15, 47]. Overall, influx of Aβ peptides into 
the brain across the BBB occurs prevalently through the 
receptor for advanced glycation end products (RAGE), while 
their clearance across the BBB is mediated mainly by the 
low-density lipoprotein receptor related protein-1 (LRP1) 
[47, 48]. RAGE receptor is significantly overexpressed in 
hippocampus and inferior frontal cortex of AD patients with 
respect to non-demented controls. Not least, RAGE proteins 
levels positively correlated with the severity of the AD 
pathology [49]. 
 Concerning the clearance of Aβ from the brain, 
lipoprotein receptor has been reported to serve as a receptor 
for Aβ precursor protein (APP) and apolipoprotein E 
(ApoE). Also soluble Aβ can be transferred by BBB 
endothelial cells from the brain to the blood, by LRP1 
binding to Aβ at the ablumenal (brain) side of the BBB 
followed by transcytosis. [15, 50]. Soluble oligomers and 
intermediate amyloids of Aβ are reported to be more 
neurotoxic than monomers and fibrils since they can interact 
with cell membrane, thus creating serious neuronal damages 
[17]. Levels of LRP are strictly related with age so it is 
considered a major risk factor for non-familial AD [45, 47]. 
 Permeability glycoprotein (P-gp) transporters are efflux 
transporters in the BBB that are responsible for the expulsion 
of toxins from brain to blood. Changes in the expression of 
this transporter have been described for different 
neuropathologies. In the case of Alzheimer’s disease the 
decrease in P-gp expression has been found to be associated 
with the increase in the deposition of Aβ neurofibrils [45, 51, 
52]. 
 Receptor-mediated transcytosis (RMT) is also highly 
affected in patients suffering from Alzheimer’s disease. 
Among the receptors involved in the case of AD, there are 
transferrin-receptor (TfR), insulin-receptor and lipoprotein-
receptor. The role of TfR is the movement of transferrin-
bound iron through the brain capillary endothelial cells by 
transcytosis. In AD affected brains, an alteration of the 
expression of the receptor is reported in the hippocampus. 
[45, 53]. It has been also reported that Aβ neurofibrils can 
compete with insulin for the receptor causing severe 
imbalances in glucose metabolism in neuropathologic 
condition [45]. 
Talking about pathological changes registered in BBB 
functionality in Alzheimer’s disease, some issues should be 
considered, as the possibility to take advantage of this 
particular condition to deliver drugs that would not be 
allowed through the barrier in a normal condition, which 
could represent a chance to find possibly more effective 
therapies. However in patients suffering from AD, the more 
severe are the changes in BBB, the higher the 
neurodegenerative level is from a cognitive point of view. So 
it becomes difficult to evaluate if the possibility of drug 
delivery offered by BBB alterations could be considered an 
advantage to treat the disease or if trying first to restore BBB 
integrity should be a priority to avoid any increase in the rate 
of degeneration [45]. 
2.4. Oxidative stress and inflammatory processes 
 There is overwhelming evidence that oxidative stress, 
inflammation and metal accumulation contribute to AD 
etiology and progression.  
 During the age-related neurodegeneration and cognitive 
decline, brain tissue is constantly exposed to oxidative stress 
characterized by an imbalance in reactive oxygen species 
(ROS) production and antioxidative defense. Detrimental 
effects of oxygen radicals have been widely reported in 
neurons of AD brains including DNA damages, lipid 
peroxidation, protein oxidation, formation of advanced 
glycation end products (AGEs), carbonyl-modified 
neurofilament proteins and free carbonyls. As clinically 
proved, markers of oxidative stress are significantly higher 
in AD patients and oxidative DNA damage of neurons and 
glia is now accepted as one of the earliest observable events 
in Alzheimer’s pathogenesis [54, 55]. Zawia and coworkers 
proposed in 2009 that the formation of stretches of 
methylated and oxidized cytosine-guanine sites can represent 
signals potentially relevant in Alzheimer’s disease 
physiopathology [56]. Oxidized guanosine form 8-oxo-G, 
which is one of the most common oxidative DNA damage 
biomarkers, can be found often associated with cytosine 
methylation. Moreover the authors proposed that the 
accumulation of Aβ-precursor-proteins and Aβ peptides can 
increase in response to early life exposure to specific stimuli, 
such as xenobiotic metals [56, 57]. 
 High levels of poly-unsaturated fatty acids and elevated 
consume of oxygen make the brain an ideal site of lipid 
peroxidation. Indeed, lipid peroxidation is one of the major 
sources of free radical-mediated injury of neuronal 
membranes. A significant number of oxidative breakdown 
products including 4-hydroxy-2,3-nonenal (HNE), acrolein, 
malondialdehyde and F2-isoprostanes have been observed in 
AD brains compared to age-matched controls [58]. These 
cytotoxic metabolites of lipid peroxidation can modify the 
redox state and the function of proteins involved in energy 
metabolism, cellular signaling, pH regulation, neuronal 
communication, neurotransmitter regulation, tau 
hyperphosphorylation, and APP processing, thus producing 
severe changes in neuronal homeostasis [59]. 
 Although a direct role for mitochondria in AD 
pathogenesis is still controversial, some evidences indicate 
that mitochondrial dysfunctions may be a trigger for AD. For 
instance, observed reduction in brain energy metabolism [60] 
and mitochondrial metabolic enzyme deficiency [61, 62] 
have been related with AD. In particular, Aβ42 has been 
identified in mitochondria where it binds to 17-β-
hydroxysteroid dehydrogenase, a mitochondrial matrix 
protein involved in fatty acid metabolism. Moreover it was 
observed that it inhibits respiratory chain function in isolated 
rat brain mitochondria [63]. Morphometric and ultrastuctural 
analysis of AD brains showed drastic alterations in 
mitochondrial dynamics and morphology such as reduced 
number, increased size and broken internal membrane 
cristae, which were found accompanied by an oxidative 
damage marked by 8-hydroxyguanosine and nitrotyrosine 
[64, 65]. 
 Alzheimer disease pathophysiology seems to be linked 
also to inflammatory processes in the brain. 
Neuroinflammation elicited by environmental and genetic 
factors might cause microglial activation, astrogliosis, as 
well as the production of inflammatory cytokines, reactive 
oxygen species, nitric oxide, glutamate and by-products of 
COX-2 reactions [66]. 
 Interestingly, activated microglia (the brain-resident 
immune cells) was found surrounding lesions in Alzheimer’s 
disease and also massive production of pro-inflammatory 
cytokines has been associated to neurodegenerative 
condition [67]. It has been hypothesized that a switch in the 
microglia cells phenotype could accelerate at some point the 
progression of the disease. In the earliest phases of the 
disease the anti-inflammatory M2 phenotype (characterised 
by secretion of the anti- inflammatory cytokines interleukin 
4, interleukin 10, interleukin 13, and TGF-β, and increased 
phagocytic capacity without production of toxic nitric oxide) 
is activated trying to clear amyloid and protect neurons. 
When M2 microglia is not quick enough to compensate the 
excessive expression of Aβ in the illness, a switch to the pro-
inflammatory M1 phenotype, promoted by the uncontrolled 
Aβ accumulation, would lead to fatal neuron damage. [68-
71]. 
 Also pathologic astrocytes can be recognized in AD and 
other neurodegenerative diseases. Like M2 microglia 
phenotype, astrocytes are involved in Aβ clearance and 
degradation. In AD patients it has been observed Aβ1-42 
accumulation in astrocytes in the enthorinal cortex [68-72]. 
 Several studies have also associated Alzheimer disease to 
a dysregulation of metal homeostasis leading to their 
abnormal accumulation into the brain of patients [73-75]. 
Besides the redox toxicity associated with the metal 
imbalance in the brain, it seems that their presence in the AD 
brain may contribute to Aβ plaque formation [76, 77]. In 
1994, Bush and co-workers reported that Aβ becomes 
amyloidogenic upon reaction with stoichiometric amounts of 
Zn2+ and Cu2+ [78, 79].). Metal ions dysregulation in AD is 
also an important aspect since it seems to directly affect 
oxidative stress, mitochondrial dysfunction, 
neuroinflammation, Aβ plaque formation and tau 
aggregation [80]. 
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Figure 3. Overview of the main pathological features of Alzheimer’s disease and the major groups of therapeutics explored to 
date  
It has been reported by Urrutia and co-workers that 
the three hallmarks of neurodegeneration just described 
(mitochondrial dysfunction, metal accumulation and 
neuroinflammation) could be involved together in a 
synergistic self-feeding cycle ending in apoptotic cell death 
[67]. 
3. THERAPEUTICS AGAINST AD
 Although many drugs are continuously in the testing 
phases for AD, no new drugs have been approved in EU and 
USA for the healing or prevention treatment in almost 15 
years (Figure 3). Up to now, only symptomatic treatments 
exist for AD. Unfortunately they act only for a limited time, 
mainly in the first phases of the illness, to delay as much as 
possible the loss of cognitive abilities of the patients. These 
treatments in the market consist mostly of cholinesterase 
inhibitors such as donepezil (Aricept; Eisai/Pfizer), 
rivastigmine (Exelon; Novartis), galantamine (Razadyne; 
Johnson & Johnson) and tacrine (Cognex; First Horizon 
Pharmaceuticals), and the N-methyl-D-aspartate (NMDA)-
receptor modulator memantine (Namenda; Forest/Lundbeck) 
[13, 81]. 
 Last research frontiers, hopes and major issues on AD 
pharmacologic treatments are described in some very recent 
reviews [13, 82]. 
 Up to now, most of the industry’s research efforts have 
been focused on the ‘amyloid hypothesis’ and associated 
targets. Several novel strategies have begun to target 
directly/indirectly the accumulation of Aβ deposits through 
the use of monoclonal antibodies, antigens, beta and gamma 
secretase inhibitors [83], and anti-amyloid aggregation 
compounds. The inhibition of γ-secretase or BACE1 is one 
of the most important fronts for AD treatment and/or 
prevention. The secretase inhibition represents an upstream 
interference with the amyloid cascade, regardless of Aβ 
species or aggregation states exerting neurotoxicity. 
 Among the new BACE1 inhibitors under active 
development are the small molecules MK-8931 (Merck), 
AZD3293 (AstraZeneca/Lilly), E2609 (Eisai/Biogen), and 
JNJ 54869111 (Janssen). These new compounds are aiming 
at finding the answers that their predecessors could not, since 
several gamma secretase inhibitors such as semagacestat 
(Lilly), begacestat (Pfizer), and avagacestat (Bristol-Myers 
Squibb) all failed in clinical studies and were consequently 
discontinued. These drugs exhibited a great potential in 
reducing Aβ in vitro and in vivo, but also leaded to a harmful 
crosstalk with Notch pathway (semagacestat) [84, 85], or to 
a progress to dementia at similar rates as patients on placebo 
in clinical studies (avagacestat). 
 More recently monoclonal antibodies, such as 
bapineuzumab and solanezumab, were developed for the 
prevention of sporadic AD by targeting Aβ peptide species 
[13, 86]. In contrast to bapineuzumab, solanezumab 
recognizes soluble monomeric Aβ, not fibrillary. It might 
sequester soluble Aβ, shifting equilibrium between different 
species of Aβ, and removing small soluble species of Aβ that 
are directly toxic to synaptic function. 
 Another front for the development of new therapies for 
AD treatment takes into account the possibility of inhibiting 
the tau pathways, in particular kinases responsible for tau 
phosphorylation. Such novel studies showed promising 
starts, in particular with compounds such as valproate, 
lithium [87, 88] and Methylene blue. Other innovative 
efforts have also begun in the development of anti-tau 
vaccines [13].Worth of mention is the study on Methylene 
Blue due to its promising perspectives until very recently. 
The compound was shown to reduce tau aggression in 
transgenic mice. TauRx Pharmaceuticals finished phase II 
clinical trials [89]. Unfortunately the results of phase III 
clinical trials disclosed in July 2016 showed that it failed to 
slow the cognitive and functional decline of Alzheimer's 
patients compared with a control. 
 Immunotherapeutic strategies for AD have been 
proposed also in the case of tau dysfunction. In particular, 
successful in vivo approaches have been exploited to target 
selectively phosphorylated tau species such as phospho-
Ser396/phospho-Ser404 [90, 91], or abnormally 
phosphorylated tau species such as phospho-Ser422 [92]. 
Overall, tau immunotherapy reduced brain pathology and 
prevented cognitive decline in mouse models. 
 Clearance of aberrant tau appears to be a valid defence 
system to prevent neurotoxicity in tauopathies. To this aim, 
the involvement of the ubiquitin proteosomal system (UPS) 
in the degradation of hyperphosphorylated tau has been 
documented [93]. Very recently, Polito and colleagues have 
reported promising results in tau clearance in AD [94]. They 
demonstrated that TFEB overexpression considerably 
reduces neurofibrillary tangle pathology and rescues 
behavioral and synaptic deficits and neurodegeneration in 
AD mouse model of tauopathy. 
 Due to the lack of a standard treatment for Alzheimer’s 
disease, also various drugs of common use have been 
proposed for its prevention, taking into account the illness 
physiopathology and the risk factors currently considered for 
AD. Among them there are antihypertensive drugs, hormone 
replacement therapy (HRT), non-steroidal anti-inflammatory 
drugs (NSAIDs), HMG-CoA reductase inhibitors (statins), 
and antidiabetic drugs. Unfortunately, up to now, the 
effectiveness of these drugs on prevention of AD still has to 
be demonstrated [82]. However, it has been experimentally 
proved that non-steroidal anti-inflammatory drugs (NSAIDs) 
significantly lower the Aβ levels. Worth of note, a recent 
meta-analysis, aiming to unravel the significant correlations 
between the anti-inflammatory drugs consumes and the risk 
of Alzheimer's disease, supports the medically-assisted use 
of NSAIDs for prevention of AD [95]. 
 It is also interesting to note that for most of the 
considered targets of the illness, intervening at the dementia 
stage may be too late. The treatment, particularly anti-
amyloid therapies, could possibly lead to better results if 
initiated earlier in the disease process. The study of such 
possibility has been hampered in last years due to the lack of 
diagnostic techniques sensitive enough. With recent 
advances in biomarker and imaging techniques it is now 
possible to identify cognitively normal individuals with 
evidence of brain amyloid, for example, often considered to 
have ‘preclinical’ or ‘asymptomatic’ AD [96]. These 
techniques open the way to test early intervention strategies 
in the very early stages of the illness (pre-dementia).  
 Finally, prevention is also an issue of major importance 
in the case of AD since most of the physiologic 
modifications due to the illness seem to be very difficult to 
reverse. 
4. BBB AND ADMINISTRATION ROUTES TO CNS
 One of the main difficulties that lead to unsuccessful 
treatments is the complicated drug delivery to the brain, 
mostly because of the presence of the blood brain barrier 
[97]. In spite of the efforts on research in the last decades, 
crossing the BBB still remains a challenge in the 
development of efficient systems (based on nanotechnology 
or not) to deliver drugs for neurodegenerative diseases 
treatment.  
 BBB is formed by a complex system of different cell 
types (endothelial cells, astroglia, pericytes, perivascular 
macrophages, and a basal lamina). One of the major 
functions of the barrier, together with the blood 
cerebrospinal fluid barrier, is to prevent the contact between 
the brain and toxic substances. In fact, 98% of all small 
molecules do not cross the BBB [98]. 
 This function of limiting the entrance of substances into 
the brain is possible thanks to tight junctions, very intimate 
cell-to-cell connections forming the so called zonula 
occludens, especially diffused in brain endothelia [50]. 
 Only small liposoluble molecules (<400 Da, with less 
than nine hydrogen bonds) can cross the BBB unassisted, via 
lipid-mediated diffusion. Such passive transport of small 
molecules through biological membranes requires their 
movement through the lipid bilayer. On the contrary, 
hydrophilic molecules can only cross the endothelial wall 
transcellularly. Transcellular bidirectional transport across 
the BBB can be classified into five main categories: carrier-
mediated transport, ion transport, active efflux transport, 
receptor-mediated transport, and caveolae-mediated transport 
[50, 98]. 
 At present, the efficacy of treatments directed to the brain 
is strictly dependent on the administration route. Due to the 
previously mentioned limitations related to the presence of 
the blood brain barrier, usually the intra-venous and oral 
administration routes are not effective. By using invasive 
methods of administration like the temporal disruption of the 
BBB integrity [99], intracerebroventricular infusion [100] or 
intracerebral implants, the drug can be administered directly 
into the brain tissue, overcoming the BBB. Nevertheless 
these methods are not convenient for use in humans for 
several reasons, including safety and costs [101, 102]. 
Among the invasive administration routes, brain infusion is 
one of the most commonly used in the case of brain illnesses 
[103]. This method consists in the local administration of the 
drug through direct injection into the brain using a catheter 
that could be stereotactically targeted to precise anatomical 
locations. The application of such methods is obviously 
limited, but still remains as the ultimate option in the case 
where physiological barriers substantially impair the 
effectiveness of any other delivery route [103]. 
A non-invasive route for brain drug delivery is the intranasal 
administration via the olfactory and trigeminal neural 
pathways [104, 105]. The intranasal administration allows 
delivering therapeutic agents preferentially to the brain since 
both the olfactory and trigeminal nerves innervate the nasal 
cavity, providing a direct connection with the CNS. This 
route of administration has been shown to present a safe and 
acceptable alternative to parenteral administration of various 
drugs [106, 107]. 
5. NANOTECHNOLOGY: A VALUABLE TOOL FOR
FUTURE MEDICINE 
Nanotechnology is a very modern science that is devoted to 
the study and understanding of matter at the scale between 1 
and 100 nm. The general properties of a material at the 
nanoscale could be very different from the properties of the 
same bulk material. This concept has been widely proven in 
the case of inorganic nanoparticles, as for example iron 
oxide nanoparticles [108]. 
At present, most of the applications based on nanosized 
materials in biomedicine can be addressed to nanoparticles. 
The importance of nanoparticles in medicine lies in the fact 
that most biochemical and biological mechanisms in the 
human body occur at the nanoscale and the same 
macrobiomolecules involved in such processes possess a 
nanoscaled size. From this point of view, nanoparticles can 
be a solid support for the delivery of different molecules and 
macromolecules for therapies or diagnosis (almost all of 
them) or, depending on the properties of the material, can be 
themselves the therapeutic or diagnostic agent (mostly 
magnetic and plasmonic nanoparticles) [109, 110]. In this 
review we will take into consideration the application of 
nanoparticles for therapy, especially drug delivery systems 
with specific targeting. 
The use of nanometric-sized particles as carriers seems very 
promising because of the protection and stabilizing effect 
that they can offer to the associated drug, and also for 
improving drug efficacy through enhanced delivery or 
residence time. The association of the drug with a 
nanocarrier can help reducing potential side-effects by 
decreasing the dose of the drug in other tissues and 
increasing the amount of drug at the desired target site. 
5.1. Nanoparticles and Alzheimer’ disease 
 Innovative drug delivery systems able to pass the BBB 
have been considered during the last 10 years as a strategic 
alternative approach for the development of treatments for 
neurodegenerative diseases, such as AD. As previously 
described, in the frame of Alzheimer’s disease, finding an 
effective therapy could be strictly related to increase the 
solubility of already tested molecules or to improve their 
ability to cross the BBB. An appropriate nanocarrier could 
help in achieving both goals. Nanoparticles of different 
nature, size and shape have already been tested as drug 
delivery systems, most of them being already proved as able 
to cross BBB [111]. 
 Generally speaking, nanoparticles are usually classified 
as inorganic (metallic, metal oxide and ceramic particles) 
and organic (lipidic and polymeric particles) (Figure 4). 
Figure 4. Main kinds of nanoparticles used in research of 
new therapies for Alzheimer’s disease. 
 Among the inorganic particles, especially magnetic and 
gold nanoparticles are widely used in nanomedicine, both for 
diagnosis and treatment. In the case of magnetic 
nanoparticles, they offer the opportunity for magnetic 
delivery of drugs, which would be ideally directed straight to 
the affected tissue under the action of a magnetic field. Both 
magnetic and gold nanoparticles can be used as therapeutic 
agents in (magnetic and optical) hyperthermia-based 
treatments. 
 Among magnetic materials, iron oxide is the most 
commonly used in biomedical applications because of its 
biodegradable nature, biocompatibility, and its 
superparamagnetic properties. At present a variety of iron 
oxide nanoparticles of different size are used for biomedical 
purposes [112-116]. 
 The use of iron oxide nanoparticles as novel carriers for 
drug delivery for neurodegenerative diseases has been 
reported in the literature [117]. They have been also tested 
for the destruction of amyloid plaques using an alternate 
magnetic field (magnetic hyperthermia) and up to now very 
promising results have been obtained in vitro [118]. 
Moreover a recent work reviewed their use as contrast agents 
for magnetic resonance imaging (MRI) to detect amyloid β 
peptide inside the brain [119]. In some cases it has been 
reported that magnetic nanoparticles were not able to cross 
the BBB to reach their target in the brain. However this 
limitation can be bypassed modifying their surface with 
appropriate compatible molecules [119]. 
 Gold nanoparticles have possibly reached even a wider 
application thanks to the reproducibility and easiness of their 
synthesis and also due to the possibility to tune their size and 
shape to obtain different optical properties [120]. Near-
infrared light is known to penetrate deep into biological 
tissues without causing ionizing damage. If gold 
nanoparticles with appropriate properties have penetrated 
into a tumor or other target tissue and a near infrared laser is 
applied on them, the particles will heat up and destroy 
surrounding cells in a process known as “photothermal 
ablation” [120, 121]. This therapy is raising attention as a 
promising strategy for light-induced destruction of Aβ 
fibrils. However, also the ability of gold nanoparticles 
themselves to cross the BBB seems to be not completely 
clear. It is reported that gold nanospheres can be used 
successfully as BBB-crossing vehicles [122]. On the 
contrary, another recent study by Yin and co-workers 
showed that the BBB crossing of gold nanostars was only 
possible through their association with a cell penetrating 
peptide [123]. Finally gold nanoparticles have been used also 
as a detection tool for Aβ peptide detection based on their 
aggregation in presence of copper ions [124]. 
 Worth of mention are also silica particles that have been 
widely studied in the nanotechnology research for diverse 
applications due to their versatile and flexible fabrication 
methods. Silica particles properties can be tuned to obtain 
different porosity of the material at the nanoscale, which 
allows their use as potential reservoirs for therapeutics or 
diagnostic agents to effectively operate as drug delivery 
systems [121]. Silica-based nanoparticles have been also 
tested for the treatment of neurodegenerative diseases [125, 
126]. 
 Most organic nanoparticles are at present widely tested 
for biomedical application due to their high biocompatibility 
and biodegradability. Lipidic nanoparticles include micelle-
based systems, liposomes, nanoemulsions and solid-lipid 
nanoparticles. To date, liposomes and micelles have 
achieved the most significant clinical success of all 
nanoparticles. Apart from the already mentioned advantages 
related to the nanoscale size of these particles, in the case of 
lipid-based particles it should be noted that they could 
enhance the solubility of hydrophobic compounds and 
improve their availability by different administration routes. 
 Liposomes are nanosized vesicles, which consist of a 
lipid bilayer enclosing an aqueous core. Structurally, 
liposomes mimic the composition of the cellular bilayer. 
They are capable of carrying hydrophilic pay-loads in their 
interior, as well as trapping hydrophobic drugs within their 
lipid membranes. Liposomes are generally divided into the 
“classical” and the “stealth” ones [127]. The classical 
liposomes present several limitations. First, they are rapidly 
uptaken by the cells of the mononuclear phagocyte system 
and they are subsequently cleared from circulation. Second, 
the retention properties of drugs inside them are strictly 
dependent on the drug nature. These aspects were solved 
with the development of Stealth liposomes, whose rigidity 
was increased with the addition of monosialoglyprotein 
GM1 and were sterically stabilized by grafting their surface 
with polyethylene glycol [127-130]. Liposomes have been 
widely used for encapsulating active molecules towards AD 
treatment. The most promising results have been reported 
with the intranasal administration of these carriers [131, 
132]. 
 Contrary to liposomes, micelles offer a reservoir for 
hydrophobic drugs in their interior. They consist of a 10–100 
nm spherical monolayer of lipids. The limitation of micelles 
consists in their need to be sterically stabilized. For this 
reason they are usually combined with PEG or other 
polymers to obtain a more rigid outer shell and afford the so-
called “polymeric micelles”. Multiple chemotherapeutics 
have been incorporated in these lipid based NPs, some 
reaching clinical use in humans [129, 133]. Moreover 
micelle-based carriers have been successfully used to target 
the brain [134, 135]. 
 Solid lipid nanoparticles consist of highly pure lipid 
crystals. The use of these systems is limited by a low drug 
loading capacity and difficult release once the lipid 
crystallization occurred. Nanostructured lipid carriers are 
mixtures of solid and liquid lipids and their imperfect crystal 
structure provides more space for accommodating the 
encapsulated drugs, thus offering better performances for 
drug delivery [128]. Solid lipid nanoparticles have been also 
used successfully for the delivery of drugs for 
neurodegenerative diseases [136]. 
 Finally microemulsion based systems are gaining interest 
in the field of biomedicine. Microemulsion is a 
thermodynamically stable colloidal system that can be 
spontaneously formed by mixing different components 
(lipid, water, surfactant and cosurfactant) together in an 
appropriate proportion. It is a very versatile system since the 
components can be varied in order to allow or improve the 
encapsulation of drugs of different nature. In the case of 
these systems, considerable amounts of drug can be 
encapsulated inside the carrier [128]. 
 Polymeric nanoparticles are being studied for drug 
delivery for the treatment of a wide range of diseases, 
including cancer, viral infections, cardiovascular diseases 
and recently also neurodegenerative diseases [137-139]. 
 They can be prepared following two approaches: (i) the 
dispersion of preformed polymers and (ii) the polymerization 
of monomers. Drug loading can be obtained either by drug 
entrapment within the polymer matrix or by drug adsorption 
on the nanoparticle surface [140]. Both methods are 
considered mild processes apart from the eventual contact of 
the drug of interest with not compatible solvents.  
 The efficacy of polymeric nanoparticles-based therapies 
depends on their careful design since the selection of the 
chemistry of the building blocks of these nanocarriers can 
drastically affect their size, payload, safety, 
pharmacokinetics and intracellular fate [140]. 
 Among polymeric nanoparticles special attention should 
be paid to nanogels [141]. They are also referred as hydrogel 
nanoparticles and the most common synthesis method used 
for nanomedicine purposes is through the formation of non-
covalent interactions between a polyion and the chains of the 
polymer (ionotropic gelation method). Also covalent binding 
can be used to form nanogels or to increase their rigidity. 
The result is a highly hydrated three-dimensional network, in 
which drugs can be easily entrapped. Due to their polymeric 
nature, a broad range of chemical modifications is possible 
on the polymer structure before the production of the 
nanogel to control the material properties. Nanogels exhibit 
high stability in vivo, tunable size, biodegradability and 
surface functionality [141]. Nanogels have been reported as 
good candidates for drug delivery for AD, especially in the 
case of intranasal administration [142, 143]. 
 Among polymers used to obtain nanogels, 
polysaccharides as chitosan and alginate are widely used for 
biomedical purposes. Chitosan is a positively-charged 
natural polymer, able to interact electrostatically with 
negatively-charged sites on a cell surface. Chitosan 
nanoparticles hold an important place in protein and nucleic 
acid delivery strategy. The cationic surface of chitosan 
nanoparticles is responsible for the mucoadhesive properties 
of the chitosan-based nanocarriers that facilitate the retention 
in the site of interest, thus providing a sustained release of 
the encapsulated drug. For this reason chitosan nanoparticles 
are considered very promising candidates for the Alzheimer 
treatments through intra-nasal administration [144, 145]. 
 Sodium alginate is a biocompatible and biodegradable 
natural polymer that has been extensively used in hydrogel-
based particles formation. Alginate presents a considerable 
potential for hydrophilic drug entrapment [140, 146]. 
 Polymeric nanocapsules can be also fabricated through 
the layer-by-layer self-assembly of polymers onto 
(sacrificial) spherical substrates, such as polymeric beads or 
inorganic templates, followed by the decomposition of this 
substrate. For drug delivery purposes, the most elegant way 
to encapsulate drug molecules inside these nanosized 
structures is via either drug-loaded templates or drug-
conjugated polymers as shell components [147]. 
Finally, dendrimers and dendritic polymers are polymers 
based in a branching repeating unit providing highly 
functionalized and compartmentalized structures. Due to 
their structure they can carry different drugs in the core 
[148]. Dendrimers behavior has been analyzed in mouse 
microglial cells and mouse neuroblastoma cells in sight of 
their more in-depth study for Alzheimer applications [149]. 
5.2. Nanoparticle targeting 
 The reported examples about drug delivery based on the 
use of nanocarriers show that nanotechnology could 
represent an important ally of medicine. The strategy of 
using specifically designed nanoparticles as carriers is 
interesting especially in the case of neurodegenerative 
diseases that are being partially handled or not handled at all. 
 Taking into account the reported difficulties currently 
hampering an efficient approach to AD treatment, there is an 
urgent need to develop more efficient strategies for drug 
delivery. An advantage of having a nanocarrier consists in 
the possibility of engineering its surface to expose proper 
ligands to drive the delivery of an active drug to a specific 
target. Generally speaking, targeting aims to improve the 
success of delivery of the compound of interest to a specific 
site of action, possibly bypassing the barriers retaining the 
therapeutic activity. By doing this, the local concentration 
and the residence time of the drug would be increased in the 
right site of action and consequently undesired effects on 
surrounding cells and tissues would be diminished.  
 There are two complementary strategies for targeting, 
passive and active, each of them relying on the 
functionalization of the nanocarrier surface with different 
kinds of molecules [150]. 
 The passive approach consists in the coating of the 
carrier surface with an inert material (organic or inorganic) 
to prevent the formation of the protein corona [151], which 
is the layer(s) of proteins and of other biomolecules that 
rapidly adsorb onto a nanoparticle as soon as it enters in a 
physiological environment [152]. A lack of control on the 
protein corona formation strongly limits the use of 
nanomaterials in medicine since the protein corona leads to 
the activation of the complement and coagulation cascades, 
opsonization and rapid accumulation in macrophages. So the 
uncontrolled nanoparticle–protein interactions can mark a 
nanoparticle for uptake in off-target cell populations and 
accumulation in determined organs [153, 154]. Using the 
strategy of passive coating the circulation time is increased 
favoring the delivery of the drug to the desired tissue [155]. 
Although passive targeting is most commonly devoted to 
render the nanocarrier surface inert to avoid any non-specific 
interaction, it can be used also to tune the physico-chemical 
properties of nanoparticle surface for controlling the level of 
cellular uptake [156]. For this purpose, most used coatings 
are charge-neutral, highly hydrophilic ‘anti-fouling’ 
polymers. In presence of these coatings, protein adsorption is 
thermodynamically unfavorable. High molecular-weight 
polymers are particularly attractive due to the high 
conformational freedom of their chains in water, which 
creates an additional entropic barrier to protein adsorption 
[152]. 
 Both cellular uptake and delivery to a target site can be 
controlled by using an active targeting on the nanocarrier 
surface. This strategy consists in linking on the particle 
surface a selection of moieties or biomolecules that are 
recognized by molecular interaction at specific sites 
(biological membranes among them). The added 
functionality of the nanocarrier can increase its affinity for 
specific cells or tissues: The most common molecular 
interactions involved are antigen–antibody or ligand–
receptor binding. In this case molecules like peptides, sugars, 
antibodies, proteins and oligonucleotides are immobilized on 
nanocarriers surface and are used as molecular Trojan horses 
[157]. 
 The presence of a molecule conjugated to the carrier is 
necessary to specifically recognize the target or carry out a 
defined activity in a biological environment. Nevertheless 
the efficiency of this recognition and/or activity strongly 
depends on the appropriate choice of the conjugation process 
[158]. There are several aspects to be taken into account 
when a functionalization protocol is going to be optimized 
for grafting an active molecule on the surface of a 
nanoparticle. The ratio between biomolecule and nanocarrier 
is one of the characteristics that should be controlled to 
correctly analyse any biological result of the targeted 
delivery [159]. Another key aspect is the functional 
orientation of the biomolecule on the surface. In fact, 
especially when a molecular recognition is involved, the 
proper orientation of a biomolecule is necessary to have the 
“active face” of the molecule available for the interaction 
with its counterpart in the biological environment (Figure 5). 
If the biomolecule is randomly attached on the nanocarrier 
surface, through non-specific chemistry or electrostatic 
interactions, only some of the molecules will eventually 
expose the active site [160, 161]. The correct orientation of 
the targeting biomolecule mostly depends on the strategy 
chosen to link it on nanocarrier surface [162]. The previously 
mentioned electrostatic interaction together with 
hydrophobic ones are usually multi-punctual weak bonds 
that lead to a strong attachment and keeps the desired 
molecule fixed on nanocarrier surface. Nevertheless, as they 
can involve practically any part of the biomolecule (apart 
from those cases in which particularly charged or 
hydrophobic chains of the biomolecule are present in a 
defined area), the result is the global random orientation on 
the surface.  
Figure 5. Schematic representation of the oriented and 
random attachment of an antibody on a nanoparticle. In an 
appropriate oriented attachment the recognition region is 
always available for interaction while not all the recognition 
elements are available in the case of a random attachment. 
 Biomolecules can be conjugated to nanocarrier surface 
also through covalent linking if the surface provides 
functional groups that can react with the molecule, both 
directly to the surface of some NPs or to surface-bound 
stabilizing ligands and coatings. This immobilization 
strategy can involve also a spacer to physically separate the 
biomolecule from the surface thus avoiding steric hindrance. 
The control over this separation distance could represent an 
important issue for some kind of applications. The use of a 
covalent strategy allows also reducing significantly the 
leaching of the molecule from the surface that represents an 
important advantage with respect to strategies based on weak 
interactions.  
 The choice of the conjugation strategy finally depends on 
the combination of nanocarrier properties and the nature of 
ligand molecule. For both factors the presence of suitable 
(and compatible) functional groups should be evaluated 
[160, 163]. All the mentioned aspects are better highlighted 
in the reported works from the literature and some have been 
also explored in systems applied to AD treatment [164, 165]. 
 The anatomical route of delivery plays an important role 
on the fate of the nanocarrier and its biodistribution. These 
two aspects can be controlled by modifying the surface of 
the nanocarrier using passive grafting or active targeting. 
This is especially important in the case of brain delivery and 
BBB limitations, since crossing the BBB remains a major 
challenge in the development of drugs and their delivery 
systems for treatment of brain diseases even after decades of 
research. 
 In the case of Alzheimer disease, the targeting on 
nanoparticle surface has been used mainly to direct a drug to 
a specific site of interest and to overcome the BBB hindrance 
or to reach both objectives at the same time. 
6. TARGETED NANOPARTICLES IN THE
TREATMENT OF AD 
 Below we have gathered a collection of the most 
representative works using targeting nanotechnological 
approaches for the treatment of AD. Interestingly inorganic 
nanoparticles have only been seldom used, for targeting or 
therapeutics using controlled local heating. Most often 
organic nanoparticles have been used as drug carriers taking 
benefit of the multivalency on their surface for targeting and 
crossing biological barriers. Among organic nanoparticles, 
liposomes are by far the most commonly used, probably 
because of their biocompatibility and the likeness of BBB 
for lipidic substances. Nanoparticles based on dendritic 
polyamines are preferred for carrying RNA or DNA. 
Nevertheless a number of excellent reviews on nanomedicine 
in the treatment of AD have already approached the topic 
after the nature of the used nanoparticles [17, 166]. Herein 
we will primarily classify the existing literature according to 
the AD feature that is addressed by the reported technology.  
6.1. Targeted nanoparticles to mitigate neuronal 
transmission dysfunctions 
 Behavioral and cognitive impairments caused by AD are 
consequence of neuronal and synaptic loss. However, most 
currently available treatments for AD aim at counteracting 
synaptic loss by using acetylcholinesterase inhibitors to 
delay as long as possible the loss of cognitive abilities of the 
patients. Being only symptomatic treatments, the effort from 
the nanotechnological point of view has been done in 
developing brain-targeted nanocarriers for already 
commercially available drugs [132, 167-169]. Table 1 offers 
an overview of reports on the use of carriers for 
acetylcholinesterase inhibitors via intranasal or targeted 
intravenous administration. 
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- Tacrine Acetylcholinesterase inhibitor [169] 
Liposomes 
CH, PC 180-220 i.n. - - Tacrine α-tocopherol 
Acetylcholinesterase 
inhibitor antioxidant [224] 
CH, PC 112 i.n. - - Galanthamine acetylcholinesterase inhibitor [132] 
LEGEND. Composition. PBCA: poly-n-butyl-cyanoacrylate. CH: cholesterol. PC: phosphatidylcholine. Routes of administration. i.n.:intranasal. i.v.: 
intravenous injection. 
 As an example Wilson et al. have developed a system of 
biodegradable poly(n-butylcyanoacrylate) nanoparticles to 
encapsulate tacrine [167] and rivastigmine [168]. For both 
drugs the encapsulation yield was nearly 90 % with a drug 
load of 17-18 % (w/w). Coating the loaded nanoparticles 
with polysorbate 80 (1 %) leaded to a small decrease in the 
drug load. The approach proved to be successful after tests 
with animals. The drug was administered to healthy male 
Wistar rats intravenously as a free drug, bound to 
nanoparticles and also bound to nanoparticles coated with 
polysorbate 80 (1 %). One hour after administration the 
concentration of rivastigmine in the brain for the loaded 
nanoparticles with polysorbate 80 group was 3.82 fold and 
3.12 fold those of the free drug rivastigmine and of the drug 
bound to nanoparticles without polysorbate 80 coating. In 
consequence, targeting ability of the nanoparticles could be 
attributed to the coating. The hypothesis is that 
apolipoprotein E and/or B adsorb on the polysorbate coating 
in the blood stream, resulting in apolipoprotein-overcoated 
nanoparticles that would mimic lipoprotein particles and 
could be taken up by the brain capillary endothelial cells via 
receptor-mediated endocytosis. 
 The same group prepared a formulation of magnetic 
chitosan microparticles loaded with tacrine for its magnetic 
targeting to the brain [169], where a suitable magnet would 
be placed. Tests in Wistar rats resulted in the magnetic 
chitosan microparticles increasing the concentrations of 
tacrine in the brain by 5.38 fold when compared to the free 
drug. 
 A more recent work takes advantage of the fast progress 
of nanocarriers suitable for non-invasive intranasal 
administration, which allows for bypassing BBB and 
therefore has been increasingly investigated for therapies for 
neurodegenerative disorders such as AD. Li et al. 2012 
loaded flexible liposomes with galanthamine hydrobromide 
(GH) and studied its pharmacokinetic behavior and 
efficiency in acetylcholinesterase inhibition in rats [132]. 
Both were greatly enhanced compared with oral 
administration. The peak concentration (Cmax) and the area 
under the time-concentration curve from 0 to 10 hours 
(AUC0→10) for intranasal administration were 3.52 and 
3.36 times higher than those of orally administered GH. 
Consistently also the peak time was greatly shortened from 
1.5 h for oral administration to 0.75 h for intranasal 
administration of GH loaded flexible liposomes. There are 
not any data for comparison with an analogous targeted 
system for intra-venous administration. 
 These works succeeded in improving the bioavailability 
of the drugs in the brain, by using nanocarriers and a 
targeting strategy. Unfortunately, contrasting neuronal 
transmission dysfunctions cannot stop or reverse the 
development of AD, although it can ameliorate the cognitive 
abilities of the patients.  
6.2. Targeted nanoparticles to block the amyloid pathway 
 Amyloid cascade hypothesis identified the accumulation 
of Aβ-peptides, either as soluble oligomers or as insoluble 
plaques, as the primary cause of AD [20, 21]. This 
hypothesis has prompted the researchers to focus in the fight 
against the accumulation of Aβ peptide species for years. In 
this issue several but not all the possible strategies have been 
followed using nanotechnology, first disaggregation of the 
existing aggregates, and second, the inhibition of the 
production of Aβ by silencing the corresponding gene. Also 
important are the development of vaccines or the use of Aβ 
targeting for localized drug delivery. The examples are 
reported in the following paragraphs. 
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* both aminoacid sequences are grafted in a single linear peptide THRPPMWSPVWPCLPFFD attached to the gold nanoparticle through the cysteine.
**Actually grafted onto the gold nanoparticle. LEGEND. Composition. DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine. CH: cholesterol. DPS-
curcumin: phospholipid – curcumin conjugate. DSPE-PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
ammonium salt. PC: phosphatidylcholine. DSPC: Distearoylphosphatidylcholine. SM: sphingomyelin. DMPA: 1,2-Dimyristoyl-sn-glycero-3-phosphatidic 
acid. DMPC: 1,2-Dimyristoyl-sn-glycero-3-phosphocholine. PEG-PLA: poly(ethylene glycol)-block-poly(lactic acid. Routes of administration. i.n.: 
intranasal; i.p.: intraperitoneal injection. i.v.: intravenous injection. i.c.v.: intracerebroventricular injection. Ligands: Methoxy XO4: 4-((E)-4-((E)-4-
hydroxystyryl)-2-methoxystyryl)phenoxy. OX26Mab: mouse monoclonal transferrin receptor antibody. AβMab: anti-Aβ1-42 monoclonal antibody. RI7217: 
anti-transferrin receptor antibody. PA: Phosphatidic acid. 19B8Mab:anti-amyloid β peptide antibody. mApoE: peptide derived from the receptor binding 
domain of apolipoprotein E (CWG-LRKLRKRLLR). ApoE3: apolipoprotein E3. TGN: Brain penetrating peptide (TGNYKALHPHNG). D-QSH: D-peptide 
sequence with binding affinity for Aβ (QSHYRHISPAQVC). THR: peptide sequence targeting transferrin receptor (THRPPMWSPVWP). LPFFD: β-sheet 
breaker peptide (LPFFD). Drug loaded. H102: β-sheet breaker peptide (HKQLPFFEED). POMD: polyoxometalate with Wells–Dawson structure.  
Figure 6. Nanoliposomes (NLs) functionalized with curcumin through thiol-Michael addition (left) and click chemistry (right) 
[171]. 
6.2.1. Recognition and disruption of the 
aggregates 
 Aβ peptides are recognized as one of the main 
pathophysiological hallmarks of AD and have become one of 
the main objectives for therapeutic and/or diagnostic 
purposes. A selection of references of nanoparticles targeted 
to Aβ species is given in Table 2. 
 There is a relatively broad variety of fragments which 
have been used on the surface of nanocarriers to target Aβ 
peptides: curcumin [170-173], lipidic fragments (e.g. 
cardiolipin, and phosphatidic acid) [164, 174-179], 
antibodies [165, 180, 181], peptides [122, 159, 182-185], and 
apolipoprotein [186]. Although some groups have focused 
their work on the development of targeted nanotools with 
potential for drug delivery or diagnosis [164, 165, 187, 188], 
some other examples have already gone beyond and reported 
not only the targeting but also the delivery of therapeutics 
aiming at disaggregating Aβ plaques and oligomers [178, 
182, 186, 189]. Nanotechnological targeted therapeutics 
under research have consisted of small drugs [170-173, 189], 
designed peptides [122, 182, 189, 190], and localized heating 
[185]. In some cases the targeting and therapeutic functions 
are exerted by the same fragment. 
 Among the small molecular drugs reported for AD, 
curcumin has been by far the most used by research groups. 
Curcumin is a polyphenolic compound derived from the 
dietary spice turmeric [191, 192]. Interestingly it shows 
affinity for Aβ peptides, and activity in disrupting the 
aggregates and in inhibiting their formation, which makes of 
it both a potential targeting agent and drug for AD treatment 
[193]. Curcumin was tested as targeting agent covalently 
linked on the surface of liposomes (130-200 nm), via either 
click-chemistry conserving the planarity of the molecule or 
through thiol-Michael addition (Figure 6) [170-173]. All 
nanoliposomes (NLs) with curcumin showed high affinity 
for fibrillar and/or oligomeric Aβ species in thioflavin T 
(ThT) and immune assays (endogenous amyloids) although 
click-curcumin NLs displayed higher affinity. Surprisingly, 
curcumin decorated NLs showed different affinity for Aβ 
peptides depending on the origin, endogenous or synthetic, 
of the peptides. Whereas, click-curcumin NLs also showed 
extremely high affinity for Aβ1-42 fibrils (105 nM) in 
surface plasmon resonance (SPR) experiments (synthetic 
amyloids), lipid-S-curcumin NLs did not bind to Aβ1-42 
monomers and oligomers in these experiments [171, 173]. 
 Interestingly, even though the curcumin was covalently 
linked on the surface of the NLs, it was able to down-
regulate the secretion of Aβ peptide in cells overexpressing 
human APP [172]. When injected in the brain of transgenic 
mouse model (APPxPS1) lipid-S-curcumin NLs could 
specifically stain Aβ deposits in vivo. Unfortunately these 
differences cannot be unarguably attributed to the linking 
functional group since a flexible oligoethyleneglycol spacer 
was used in the click-curcumin NLs and not in the lipid-S-
curcumin NLs. The NLs diffused locally along the injection 
tract and, on a longer distance, along the fibers of the corpus 
callosum. This diffusion could be attributed to the NL 
carrier, since fluorescent NLs, devoid of curcumin, showed 
the same diffusion properties [172]. 
Despite the high affinity for Aβ with which curcumin 
imparted the nanocarrier, intracranial administration was 
required in the absence of a targeting agent for crossing the 
BBB [172]. For this reason most of the groups follow 
approaches that include strategies to go across the blood 
brain barrier and target the Aβ.  
 Methoxy-XO4 is another low molecular weight 
compound that is currently used as a fluorescent Aβ probe 
for the detection and quantification of plaques, tangles and 
cerebrovascular amyloid. Tanifum et al. used this fragment 
to prepare an Aβ-targeting fluorescent lipid conjugate 
[DSPE-PEG-3400-XO4] that was included in the 
formulation of pegylated liposomal nanocarriers [187]. Aβ 
plaque deposits were bound in vivo after intravenous 
injection in an AD mouse model (APP/PSEN1 transgenic 
mice) labeling parenchymal Aβ deposits and vascular Aβ 
peptide characteristic of cerebral amyloid angiopathy. The 
delivery across the BBB relied on the long circulating time 
of the liposomes as a result of the PEG coating (passive 
targeting) and also on the brain penetrating capacity of the 
XO4 fragment. The system was the first successful design 
for intravenous delivery of Aβ-targeted liposomal 
nanocarriers [187]. 
 Anionic phospholipids cardiolipin (CL) and phosphatidic 
acid (PA) also showed very high affinity to Aβ1-42 and its 
aggregated forms when decorating NLs and solid lipid 
nanoparticles [174]. The affinity for Aβ1-42 fibrils was 
studied by SPR and ultracentrifugation on a discontinuous 
density gradient. Low binding of NLs incorporating PA or 
CL was detected on immobilized Aβ1-42 monomers. In 
contrast, the affinity of liposomal PA or CL for Aβ1-42 
fibrils and oligomers was very high, with values in the 
nanomolar range for the fibrils. Multivalence likely plays a 
key role in such a high affinity. The selectivity was 
qualitatively shown by the absence of binding to bovine 
serum albumin. 
 After having shown the applicability of the system for 
Aβ targeting, Re et al. provided the sphingomyelin-
cholesterol-CL (or PA) NLs with the ability of crossing the 
BBB by functionalizing them with ApoE-derived peptides 
(141-150 monomer and its tandem dimer) [175, 176. 
Fluorescence and radiochemical assays showed that the 
functionalization of the NLs with ApoE-derived peptides 
allowed their uptake by a rat brain endothelial cell line 
(RBE4) in contrast to non-functionalized NLs. Increasing the 
density of functionalization increased the uptake of the NLs 
and also the transendothelial permeability. Although the 
monomer functionalized NLs were better internalized by 
cells, the dimer delivered significantly higher 
transendothelial permeability values [175, 176]. The 
presence of the ApoE-derived peptides on the surface did not 
affect the ability of the NLs to bind Aβ1-42 peptide in vitro. 
 Subsequently the system was tested in in vivo 
experiments in 2013. Similar bifunctionalized NLs with a 
modified ApoE-derived peptide to cross the BBB and 
phosphatidic acid to target amiloyd β peptides, exhibited 
much higher permeability across the BBB either in vitro (5-
fold) or in vivo in healthy mice with respect to the NLs 
functionalized only with phosphatidic acid [177]. 
Biodistribution studies of radiolabeled mApoE-PA-NL after 
intravenous injection in healthy mice showed just 0.30 % of 
the total dose was located in the brain compared to 0.17 % of 
PA-NL [177]. Intraperitoneal administration (three injections 
per week, for 3 weeks) in 10 month-old APP/presenilin 1 
transgenic mice leaded to a 33 % of brain insoluble Aβ1-42 
peptides. Brain Aβ oligomer were also drastically reduced. 
Meaningfully, Aβ peptide amount increased 20 % and 18 % 
in spleen and liver respectively [178]. More recently 
fundamental fluorimetric studies have been conducted on the 
interaction of Aβ oligomers with this class of liposomes 
[179]. 
 Full-length recombinant ApoE3 was used by Song et al. 
in combination with 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) based liposomes [186]. In contrast 
to other reports of ApoE3 decorated liposomes, in this case 
there was a direct interaction of ApoE3 with the lipids in the 
liposome. The novel nanostructure, which the authors named 
as apolipoprotein E3 reconstituted high density lipoprotein 
(ApoE3-rHDL), displayed a relatively small size (20-30 nm). 
Surface plasmon resonance, transmission electron 
microscopy, and co-immunoprecipitation studies 
demonstrated the high binding affinity of ApoE3-rHDL to 
both Aβ monomer and oligomer, similar to natural ApoE3-
rHDL and higher than ApoE3 alone. The clearance of Aβ 
was emphasized. In vitro studies showed accelerated 
microglial, astroglial and liver cell degradation of Aβ by 
facilitating the lysosomal transport. One hour after 
intravenous administration in mice the amount of 125I-
ApoE3-rHDL accumulated in the cerebral cortex and 
hippocampus were 0.41-0.43 % of the administered dose, 
comparable to well-acknowledged nanocarriers for brain 
targeting drug delivery. Studies using senescence-accelerated 
prone mouse (SAMP8) showed that intravenous 
administration of ApoE3 rHDL succeeded in decreasing Aβ 
deposition, attenuating microgliosis, ameliorating neurologic 
changes, and rescuing memory deficits. A four week daily 
administration proved to be safe although it is obviously a 
short-term treatment taking into account the nature of AD 
[186]. 
 The utilization of monoclonal antibodies or synthetic 
peptides may be preferable over the actual substrate of the 
receptors, as they do not need to compete with endogenous 
molecules but still grant the capability to enter brain 
capillary endothelial cells (BCECs) by receptor mediated 
endocytosis [44]. ApoE derived peptide was substituted by 
the anti-transferrin receptor antibody RI7217 in phosphatidic 
acid functionalized nanoliposomes (RI-PA-NLs) [164]. 
RI7217 was conjugated to the tip of polyethylene glycol 
molecules at the surface of the liposomes, through a biotin-
streptadivin linkage or through thiol-maleimide covalent 
ligation. Conjugation with RI7217 leaded to higher values of 
uptake and permeability across the barrier model in 
comparison with non-functionalized ones, although a 
superior performance was reported for the direct covalent 
coupling of RI7217 compared to biotin-streptadivin linkage 
[164]. Confocal microscopy experiments illustrated that RI-
PA-NLs were not transported via the endosome–lysosome 
pathway, suggesting receptor-mediated transcytosis as a 
possible transport mechanism across the BBB model. 
Although the results of permeation in vitro were slightly 
worse than using ApoE derived peptide [164, 175], this work 
shows the importance of the nature of the chemical binding 
of the targeting ligand. 
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Figure 7. Schematic representation of two of the liposome series studied by Loureiro et al. for the effect of the chemical 
linkage on the performance of dually functionalized liposomes [165]. Left, liposomes functionalized with OX26MAb and 
19B8Mab respectively through streptavidin-biotin complex and thiol-maleimide chemistry. Right, the second series of 
liposomes functionalized with OX26MAb and 19B8Mab respectively through thiol-maleimide chemistry and streptavidin-
biotin. 
 Dual targeting for Aβ peptides and BBB, and the 
importance of the chemical binding nature of the targeting 
fragments to the liposomes were also explored by Loureiro 
et al. using DSPC (1,2-distearoyl-sn-glycero-3-
phosphocholine), Chol (cholesterol ovine wool), DSPE-
PEG2000 pegylated liposomes [165]. The anti-transferrin 
receptor monoclonal antibody (OX26MAb) was used to 
address the BBB and an anti-Aβ peptide antibody 
(19B8MAb) was used to recognize the Aβ aggregates. 
Different kind of liposomes were tested, with just one of the 
ligands, or with both, each one attached to the liposomes via 
biotin-streptavidin complex or through maleimide (Figure 7). 
In contrast to other reports the cellular uptake of the 
liposomes was much more efficient when OX26MAb was 
conjugated through streptavidin–biotin complex instead of 
the maleimide group [165]. The authors hypothesized that 
the presence of two antibodies, one of them bound to biotin-
streptavidin, could generate the formation of different layers 
to minimize lateral repulsions between the proteins: 
OX26MAb would be more available in the system with two 
antibodies if linked through the streptavidin–biotin system 
instead of the maleimide group. Additionally, the results in 
vitro indicated that the transport across the BBB could also 
be assisted by the 19B8MAb since it has been suggested that 
anti-Aβ antibodies cross slowly the BBB by extracellular 
pathways [194]. 
 In this line Markoutsa et al. have also reported on the 
apparent interaction between targeting ligands in dually 
targeted liposomes [180, 181]. In this case, similar 
permeability values were observed for liposomes decorated 
through the biotin-streptavidin complex with OX26MAb and 
anti-Aβ-MAb and liposomes functionalized only with 
OX26MAb. Since the detrimental effect of a second 
antibody on the same vesicle for the uptake of OX26MAb 
functionalized liposomes had already been reported, the 
authors decided to explore the occurrence of independent 
additional interactions induced by the second antibody [180, 
181]. Indeed, liposomes functionalized only with anti-Aβ-
MAb also showed higher uptake by hCMEC/D3 cells than 
the control liposomes. The uptake values also increased by 
2-2.5 times, when incubations were carried out in the 
presence of Aβ1-42 peptides. Finally, experiments blocking 
the RAGE receptors, which is the receptor primarily 
responsible for the Aβ1-42, proved that RAGE receptor was 
involved in the transcytosis of the anti-Aβ-MAb 
functionalized liposomes. The authors suggested that higher 
differences would be observed if the orientation of the 
antibody on the liposome was controlled [181]. 
 There are some arguments against the use of monoclonal 
antibodies for targeting: they can give rise to immunogenic 
response and it is difficult to develop protocols for the 
appropriate orientation of the antibody on the nanoparticle. 
Some of these issues can be addressed with the use of 
engineered peptides. Zhang et al. proposed a system using 
pegylated polylactic acid nanoparticles which were targeted 
for BBB and Aβ1-42 by using two peptides, 
TGNYKALHPHNG (shortened as TGN) and 
QSHYRHISPAQV (shortened as QSH), which had been 
screened by phage display for penetrating the BBB and 
recognizing Aβ1-42 respectively [159]. Both peptides were 
covalently attached to the nanoparticles by thiol-maleimide 
chemistry, with a degree of functionalization that was 
optimized to obtain the maximal targeting effect. 
Monofunctionalized nanoparticles with TGN (TNP) or QSH 
(QNP) respectively showed high uptake by immortalized 
mouse brain endothelial cells (bEnd.3 cells), and high 
affinity for Aβ1-42 in thioflavin T (ThT) binding assay and 
SPR measurements. Biodistribution experiments after 
intravenous injection in mice with coumarin-loaded dually 
targeted nanoparticles (TQNP) afforded a drug targeting 
index (DTI) of 2.05, 2.11 and 3.77 for cerebrum, cerebellum 
and hippocampus respectively [159]. This system was later 
studied for the encapsulation of a β-sheet breaker peptide, 
HKQLPFFEED (shortened as H102) [182]. The loading 
capacities of the H102-loaded nanoparticles were 
approximately 0.54–0.61% with an encapsulation efficiency 
of 58 % for the nanoparticles functionalized with TGN and 
QSH at the same time (TQNP/H102). Tests in the AD model 
mice showed an increased accumulation of H102 at brain 
Aβ1−42 which leaded to better and neuroprotective effects 
with dually targeted nanoparticles (TQNP/H102) compared 
to non-modified (NP/H102) or TGN-modified nanoparticles 
(TNP/H102). Beyond the ability of this system for 
penetrating into the CNS and for targeting the AD brain 
lesions [159], this study confirms the suitability of the 
system as carrier for peptide drugs which otherwise would 
lack of stability, circulation time and/or permeation through 
the BBB [182]. 
 Kumaraswamy et al. used another kind of peptide, a β-
sheet breaker peptide KLVFF, in combination with curcumin 
to fight the cytotoxicity caused by Aβ peptides [189]. In this 
approach curcumin and KLVFF were encapsulated in 
liposomes formed by phosphatidylcholine and 1,2-
distearoyl-sn-glycero- 3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] ammonium salt (DSPE-
PEG(2000)). Targeting was achieved by functionalization of 
the surface with lactoferrin via thiol-maleimide linkage. 
Rather low encapsulation yield for KLVFF of 35 % was 
observed which further diminished to 22 % when curcumin 
was also encapsulated. The peptide was proved to intercalate 
between the phospholipid acyl chains of the lipid carrier. 
Release kinetics of curcumin and peptide from the liposomal 
carrier followed the matrix type system. The efficacy of the 
formulation was tested by cell viability assays using IMR-32 
neuroblastoma cells incubated with Aβ1-42 peptide [189]. 
 BBB crossing can be achieved, not only by receptor 
mediated mechanisms, but based on the size of the 
nanocarrier. Gao et al. developed a system consisting of gold 
nanoparticles grafted with polyoxometalates with Wells-
Dawson structure, AuNPs@POMD, with a total 22 nm size 
[122]. POMDs had been previously reported to inhibit Aβ 
aggregation by binding a cationic cluster from His13 to 
Lys16. β-sheet breaker LPFFD peptide was derived from the 
Aβ central hydrophobic region from Leu17 to Phe20, right 
next to the cationic cluster. The authors rationalized that 
decorating AuNPs@POMD with LPFFD peptide should lead 
to a larger binding site on Aβ and thus to exhibit greater anti-
Aβ toxicity for the therapy of Alzheimer’s disease. LPFFD 
peptide was incorporated as CLPFFD (pep) using the 
cysteine at N-terminus to bind the gold nanoparticles via Au-
S chemistry. The authors evaluated the half maximal 
inhibitory concentrations (IC50) for the quantification of the 
inhibitory effects of AuNPs@POMD, NAc-CLPFFD and 
AuNPs@POMD-pep. The IC50 value of AuNPs@POMD-
pep was approximately 6.14 and 4.31 times lower than those 
of N-Ac-CLPFFD and AuNPs@POMD, respectively, which 
suggests that the inhibitory efficiency of AuNPs@POMD-
pep was markedly increased due to the synergistic effects of 
AuNPs@POMD and the peptide. Interestingly a synergistic 
effect was also found in the decrease of Aβ-mediated 
peroxidase activity and of Aβ-induced cytotoxicity. Finally 
inductively coupled plasma mass spectrometry (ICP-MS) 
studies after intravenous administration in mice showed 
AuNPs@POMD-pep could cross the BBB [122]. 
 Gold nanoparticles, also linked to CLPFFD peptide for 
Aβ recognition, were used in combination with microwave 
irradiation to inhibit irreversibly the normal aggregation of 
Aβ peptides in solution. The resulting irradiated products 
were not amyloidogenic [183, 184], thus the peptides were 
probably denatured by the optothermal effect. The system 
was later designed to cross BBB in in vivo experiments. By 
conjugating a V shaped peptide to the AuNP through a 
cysteine residue in the lower part of the V. One of the upper 
parts contained a directing portion (THR) to vectorize the 
peptide to the transferrin receptor and lead the system across 
the blood-brain barrier, and the other a 
recognition/attachment portion (LPFFD) for the Aβ 
aggregates. In vitro, AuNP-THR-LPFFD constructs were 
able to cross the model of BBB, with a noticeable synergistic 
effect between the two peptidic fragments. However 
biodistribution analysis after intraperitoneal injection and 
transcardial perfusion with PBS in rats, showed only small 
amounts of conjugates in the brain parenchyma compared to 
the administered doses (0.07 %) [185]. The fact that both 
targeting functions are contained in one V-shaped peptide 
could originate detrimental interactions. 
The utilization of an external radiation source was also 
envisaged in a drug delivery system developed by Xu et al. 
[188]. Instead of implementing a targeted system, the 
researchers designed a nanocarrier that would only release its 
cargo in the presence of Aβ oligomers. The drug carrier 
design consisted of a graphene-mesoporous silica hybrid 
(GMS)-supported lipid bilayer, inspired from Aβ oligomer-
mediated cell membrane disruption in the pathogenesis of 
amyloidosis. Aβ peptides are not specifically targeted, but 
drug release would only take place in their presence, as they 
trigger the disruption of the lipid bilayer. As a second 
mechanism to ensure drug release, the use of a near-infrared 
laser was also introduced taking advantage of the 
photothermal effect of GMS and thermal sensitivity of lipid 
bilayers, which also implied the use of a fluorescent dye 
assess when the laser had to be turned on. Unfortunately the 
system lacks the capacity to cross the BBB [188]. 
 Intranasal administration was chosen for the delivery of a 
β-sheet breaker peptide H102 [190]. Despite affording 
promising results after intraventricular administration, the 
peptide drug showed low penetration through BBB and very 
low stability in vivo, being cleared rapidly after intravenous 
injection with a plasma half-time less than 2 min. the 
encapsulation of the peptide drug in phospholipid-based 
liposomes clearly improved its nasal mucosa permeation of 
the drug and extended its stability in plasma. In experiments 
with rats the AUC of the encapsulated drug after intranasal 
administration was 2.69 times higher than that of a H102 
solution using a 1 % chitosan to favor the absorption. The 
transport to the brain was also improved: The drug amount in 
the hippocampus of groups that received liposomes was 2.92 
times higher than that of the given solution of peptide and 
chitosan. The efficacy of the system in AD treatment was 
assessed based on behavioral experiments, on the detection 
of acetylcholinesterase (AchE), choline acetyltransferase 
(ChAT) and insulin degrading enzyme (IDE) activity, and on 
histological assays for the plaque deposition [190]. 
Very recently the encapsulation of tarenflurbil in poly 
(lactide-co-glycolide) nanoparticles (TFB-NPs) and solid 
lipid nanoparticles (TFB-SLNs) has been reported [195]. 
Tarenflurbil is a Aβ1-42 selective lowering agent and γ-
secretase modulator, which failed in phase III trials in 2008. 
Its failure is generally attributed to an insufficient ability to 
penetrate the brain [196]. A series of surfactants were tested 
to obtain a good encapsulation efficiency and nanoparticle 
size both for polymeric and solid lipid nanoparticles. Plasma 
and brain pharmacokinetics were studied after single dose 
and multiple-dose intranasal administration in Sprague 
Dawley (SD) rats. Compared to intravenous, intranasal and 
oral administration of the free drug, concentration of 
tarenflurbil in the brain was improved when the drug was 
loaded in nanoparticles and administered following the 
intranasal route [195]. 
6.2.2. Prevention of Aβ peptides production 
 Although most AD therapies in research are based in Aβ 
peptides recognition and disruption of their oligomers and 
plaques, another approach under investigation aims at the 
down-regulation of their production [197-200]. Aβ peptides 
originate from the proteolytic cleavage of the amyloid 
precursor protein APP, performed by a series of secretase 
proteins. β-site APP cleaving enzyme 1 (BACE1, β-
secretase) cleaves APP to a 99 amino acid fragment, 
initiating the sequence that eventually leads to the formation 
of the amyloid peptides with 40-42 aminoacids which are the 
major components of amyloid plaques and oligomers [201]. 
Although up-regulation of BACE1 has been associated to 
AD cases, down-regulation of this protein has also been 
reported to lead to behavioral and physiological deficits 
[197]. The development of several low molecular weight 
BACE inhibitors is currently in course but to our knowledge 
the nanotechnological approach to this AD aspect has been 
centered in the regulation of BACE by targeted gene therapy. 
A smart nanocarrier designed for this job requires of 
targeting agents able to facilitate the internalization across 
BBB and by the neurons (Table 3). That is the case of rabies 
virus glycoprotein (RVG29) peptide, a 29-amino-acid 
peptide, which can bind to the acetylcholine receptor, present 
not only in the vascular endothelium of BBB but also in the 
membrane of neurons. 
Figure 8. Schematic representation of production, harvest 
and re-administration of targeted self-exosomes for gene 
delivery as reported by Alvarez-Erviti et al. Reprinted by 
permission from Macmillan Publishers Ltd: [Nature 
Biotechnology] [198], copyright (2007). 
 In a pioneering work, Alvarez-Erviti et al. used 
transfected dendritic cells to produce exosomes expressing 
RVG29 on their external surface (Figure 8) [198]. 
Appropriate siRNA was introduced in the purified exosomes 
by electroporation. Due to RVG29 action intravenously 
targeted exosomes delivered siRNA specifically to neurons, 
microglia and oligodendrocytes in the brain, resulting in a 
specific gene knockdown. When exosomes were 
administered intravenously to normal C57BL/6 mice a 
significant protein knockdown (62%, P < 0.01) was observed 
in BACE siRNA-RVG exosome-treated mice resulting from 
a significant decrease in BACE1 mRNA levels (61% ± 13%, 
P < 0.01), which leaded to a significant decrease (55%, P < 
0.05) in the total Aβ1-42 levels. BACE1 knockout did not 
have an overt effect on the mouse phenotype suggesting 
BACE1 inhibition might be free of side effects. 
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Table 3. Targeting nanoparticles aiming at treating AD through the reduction of Aβ production or through immunotherapy 
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* The drug carrier was formed by several polymer particles surrounding the siRNA by electrostatic interactions. ** The drug carrier was formed by several
DGL-PEG particles surrounding the pshBACE1-AS by electrostatic interactions. *** D-Pep is actually grafted onto DGL-PEG. LEGEND. Composition. 
Poly(mannitol-co-PEI): branched polyethylenimine crosslinked with mannitol diacrylate. CH: cholesterol. YSK05: 1-methyl-4,4-bis(((9Z,12Z)-octadeca-
9,12-dien-1-yl)oxy)piperidine. PEG-DMG: 1-(monomethoxy polyethyleneglycol 2000)-2,3-dimyristoylglycerol. DGL-PEG: PEGylated dendrigraft poly-L-
lysine. DMPC: Dimyristoylphosphatidylcholine. DMPG: dimyristoylphosphatidyl glycerol. MLPA: Monophosphoryl lipid A. S1P: D-erythro-sphingosine-1-
phosphate. DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine. POPG: 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt. Routes of 
administration. i.v.: intravenous injection. i.c.v.: intracerebroventricular injection. s.c.: subcutaneous injection. Ligands. RVG29: rabies virus glycoprotein 
peptide (sequence: YTIWMPENPRPGTPCDIFTNSRGKRASNG). ApoE: apolipoprotein. Drug loaded. BACE1 siRNA: small interfering RNA for BACE1. 
pshBACE1-AS: Plasmid encoding a short hairpin RNA against BACE1 antisense, a natural antisense transcript non-coding RNA that regulates BACE1 
expression. D-Pep: all D amino-acid peptide inhibitor of tau fibril formation (sequence: D-TLKIVW). Synt-Aβ1-42: synthetic amyloid β peptide formed by 42 
residues. 
 Recently, the same strategy has been applied using 
polyamines for targeted gene delivery [197, 199]. 
Heterobifunctionalized linear PEG fragments were coupled 
on one tip to the polyamine via an amide bond, whereas 
RVG29 was coupled on the other tip through thiol-
maleimide covalent ligation. RNA or DNA were complexed 
via electrostatic interaction with the polyamine. Further 
functionalization or targeting to other aspects of AD could 
be incorporated covalently conjugated [197]. Employment of 
RVG peptide on the surfaces of complexes largely increased 
the silencing efficiency more than two folds using Neuro2a 
and SH-sy5y cell lines which are originated from neuronal 
cells while there was no evident increase of silencing effect 
using HepG2, A549, C2C12 and HeLa cells [199]. In vivo 
studies showed the BACE1 silencing efficiency of this kind 
of complexes both for in hippocampus and cortex parts in 
AD, reaching 2.32-fold and 3.03-fold reduction in in vivo 
gene silencing of BACE1 expression respectively in cortex 
and hippocampus [199]. 
 In a closely related approach Tamaru et al. used a 
liposomal nanoparticle containing a proton-ionizable amino 
lipid (YSK-MEND). The encapsulation of the nucleic acids 
was driven by ionic interactions whereas the liposomal 
external surface was functionalized with recombinant ApoE. 
Although the studies showed the capacity of the system to 
knock gene expression down, the way of administration for 
the in vivo experiments was intraventricular injection, thus 
limiting the applicability of the system [200]. 
6.2.3. Anti-Aβ Vaccine 
 Active immunization strategies have also been tested 
against AD, normally by the controlled administration of Aβ 
peptides or fragments of them. There are several promising 
reports in the literature which use nanoliposomes for a better 
administration (Table 3). 
Figure 9. Design of the two liposomal vaccines containing 
peptide immunogens with the first 16 (ACI-01, Aβ1-16) and 
15 (ACI-24, Aβ1–15) amino acids of the full length Aβ1–42 
peptide. (A) In ACI-01 two PEGylated lysine residues act as 
covalently linked spacers between the antigen, Aβ1–16, and 
the liposome. For ACI-24, the antigen was anchored to the 
liposome through a terminal palmitoylated lysine residue 
covalently linked at each end of Aβ1–15. (B) Sequence of 
the peptides integrated into the liposomal vaccines ACI-01 
and ACI-24. Reproduced by permission from [207] 
 First attempts for vaccines against AD leaded to a clinical 
trial of active immunization with aggregated synthetic 
A𝛽1−42 peptide/QS21 adjuvant against A𝛽 in patients with 
AD in 2001 [202]. The immunization was successful in 
patients with an abbreviated immunization protocol, by 
generating anti-A𝛽 antibodies, reducing cerebrospinal levels 
of tau, and reporting a slower cognitive decline. However, 
the clinical trial had to be interrupted because of a significant 
number of meningoencephalitis among the immunized 
subjects probably induced by an extensive T-cell-mediated 
immune response [202]. In order to overcome this problem, 
Carrera et al. developed a system (EB101) consisting of 
A𝛽1−42 and sphingosine-1-phosphate emulsified in a 
phospholipid liposome complex [203-205]. Monthly 
intraperitoneal administration (9 injections, 7 months) of 
EB101 to APP/PS1 mice before the onset of A𝛽 deposition 
and/or at an older age was effective in halting the 
progression and reducing the AD-like neuropathological 
hallmarks: A𝛽 plaques, neurofibrillary tangle-like structures, 
activated astrocytes, and neuroinflammation. The success of 
the formulation compared to the non nanotechnological 
approach would reside in the codelivery of sphingosine-1-
phosphate to stimulate an anti-inflammatory reaction and act 
as a neuronal regenerating agent in in vitro and in vivo 
studies. In spite of the promising results to our knowledge 
the vaccine is not under clinical trials yet. 
This kind of inflammatory reaction was not addressed by 
Songjiang et al., who used chitosan nanocarriers for 
delivering Aβ antigen to the brain [206]. 
 ACI-24 is another liposome vaccine that was also 
designed to elicit an antibody response against aggregated 
Aβ peptides [207-209]. This vaccine consists of 
tetrapalmitoylated preparations of N-terminal Aβ fragments, 
which rapidly stimulate anti-Aβ antibodies that dissolve Aβ 
fibers in vitro and in vivo (Figure 9). Pro-inflammatory T 
cell activation is prevented by using the truncated Aβ-15 
sequence, thus lacking T-cell epitopes located closer to the 
peptide’s C-terminus. Each Aβ1-15 sequence was 
functionalized with palmitoylated lysines at either end, so 
that it was anchored into the surface of liposomes in such a 
way that the peptides adopted an aggregated β-sheet 
structure, forming a conformational epitope. When PEG 
fragments were used as spacers between the liposome and 
the Aβ1-15 sequence, its conformation was changed and the 
efficacy of the vaccine was compromised (ACI-01 in Figure 
9). For preclinical studies ACI-24 was repeatedly 
subcutaneously injected together with the adjuvant 
monophosphoryl lipid A (MPLA) into APPxPS-1 transgenic 
mice and into cynomolgus monkeys. The treatment 
generated high titers, which involve a non-inflammatory Th2 
helper cell response. The concentration of insoluble Aβ40 
and 42 and of soluble Aβ42 decreased after a three-month 
treatment study in APPxPS-1 mice. Interestingly it also 
improved novel object recognition while causing neither 
gliosis nor increases in measures of pro-inflammatory 
cytokines. ACI-24 is being currently evaluated for the 
treatment of Alzheimer's disease in Down's syndrome, a 
genetic condition that leads to brain Aβ deposition and 
dementia in mid-life [210]. 
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* The drug carrier was formed by several DGL-PEG particles surrounding the pshBACE1-AS by electrostatic interactions. ** D-Pep was actually grafted onto
DGL-PEG. LEGEND. Composition. DGL-PEG: PEGylated dendrigraft poly-L-lysine. DMPC: Dimyristoylphosphatidylcholine. DMPG: 
dimyristoylphosphatidyl glycerol. CH: cholesterol. MLPA: Monophosphoryl lipid A. S1P: D-erythro-sphingosine-1-phosphate. Routes of administration. 
i.v.: intravenous injection. s.c.: subcutaneous injection. Drug loaded: pshBACE1-AS: Plasmid encoding a short hairpin RNA against BACE1 antisense, a 
natural antisense transcript non-coding RNA that regulates BACE1 expression. D-Pep: all D amino-acid peptide inhibitor of tau fibril formation (sequence: D-
TLKIVW). Tau-fragment: tetrapalmitoylated 16-mer synthetic peptide corresponding to human protein Tau sequence 393–408, with phosphorylated residues 
S396 and S404.  
Figure 10. Dual drug –loaded nanoparticles reported by Liu et al. Polyamine, dendrigraft polylysine, is first reacted with NHS-
PEG3500-maleimide chains. The maleimide groups are then used for further functionalization with two functional peptides 
RVG29 and a D-peptide. Finally, the polycationic nature of polylysine at physiological pH is used for the electrostatic 
interaction with a plasmid [197].  
6.3. Inhibition of tau protein aggregation 
 In spite of being another major lesion in AD, less 
therapeutic attention has been paid to intracellular fibrillary 
tangles, which also holds for nanotechnological approaches. 
Intracellular fibrillary tangles appear to be downstream to 
A𝛽 lesions [22], which has leaded to give more importance 
to A𝛽 aggregates. There are few reports on targeted 
nanoparticles against tau aggregation as shown in Table 4. 
 In an outstanding work of 2016, Liu et al. reported a 
multifunctional nanocarrier for therapeutic gene and peptide 
co-delivery treating the two main hallmarks of AD [197]: Aβ 
plaque deposition and inhibition of tau-related fibril 
formation. Dendrigraft polylysine was chosen as the vehicle 
for the double therapy. Part of the amine groups could be 
used for pegylation and covalent functionalization with thiol 
maleimide chemistry with RVG29 and a D-peptide (Figure 
10). The former was used to interact with acetylcholine 
receptor in the BBB and neurons for receptor mediated 
endocytosis. The latter is a peptide computer-designed to 
interact with tau-protein and break its oligomers [211]. The 
strategy against Aβ plaque deposition consisted of the down 
regulation of BACE by delivering a non-coding RNA 
plasmid already treated above. The plasmid interacts with the 
rest of amino groups of the dendrigraft polylysine via 
electrostatic interactions. Double fluorescence experiments 
with labeling of the plasmid and the D-peptide demonstrated 
that both therapeutic agents were internalized simultaneously 
by cells. There was some dissociation between the plasmid 
and the rest of the carrier after cellular uptake, which is a 
desired feature as the plasmid therapeutic action has to be 
exerted in the nucleus whereas the D-peptide has to work in 
the cytoplasm. In vivo experiments also with double labeling 
demonstrated that this system is able to deliver DNA and D-
peptide to the brain after intravenous administration, thanks 
to the targeting ability of RVG29 peptide. Administration to 
AD model mice (APP/PS1 transgenic mice) succeeded in 
downregulating BACE to levels comparable to non-
transgenic mice. Tau-positive immunostaining experiments 
showed that nanoparticles with D-peptide modification 
produced a decrease in the tau positive signals, 
demonstrating that D-peptide played a role in disrupting the 
fibril formation in hippocampus [197]. 
6.3.1. Anti-tau Vaccine 
 Similar to amyloid related vaccine ACI-24, tau-related 
vaccine ACI-35 is a liposome-based vaccine that uses 
monophosphoryl lipid A (MPLA) as adjuvant. In this case 
the immune response is directed to pathological conformers 
of phosphorylated tau proteins. The vaccine consists of 
liposomes displaying 16 copies of a synthetic tau fragment 
that is phosphorylated at the protein’s pathological 
phosphorylation residues S396 and S404. The design 
prevents autoimmune B cell or T cell responses against 
physiological forms of this important intracellular protein 
[208, 212]. 
 The vaccine was successful in generating high titers of 
polyclonal IgG antibodies specifically directed against 
phosphorylated tau, rather than non-phosphorylated tau after 
a three-month regimen of subcutaneous ACI-35 injection in 
both wild-type C57BL/6 and P301L mutant tau transgenic 
mice. ACI-35 treatment increased retention of body weight, 
delayed onset of a clasping motor phenotype, and extended 
lifespan, but it did not improve endurance on a rotarod test. 
Inflammatory markers resulted negative in this preclinical 
study [213]. Phase 1b study was completed in 2015 and 
ACI-35 was licensed to Janssen the same year. 
6.4. Treatment of inflammation or oxidative stress 
 As a result of the multifactorial and heterogeneous nature 
of AD, compounds with multiple properties are very good 
candidates for the treatment. Curcumin is a molecule with 
diverse properties including antiinflammatory, antioxidant, 
antiproliferative, and antiangiogenic activities [191, 192], 
some of which can be very helpful for the treatment of AD 
patients. It is known to have anti-Aβ and anti-tau 
hyperphosphorylation properties, as well as to regulate the 
secondary changes such as oxidative and inflammatory stress 
and cholesterol regulation [191-193]. Several approaches 
have been developed for the encapsulation of this drug, as it 
is hydrophobic and insoluble in water, which limits its 
bioavailability and its application. 
 Jaruszewski et al. synthesized nanovehicles carrying 
curcumin or dexamethasone complexed hydroxypropyl-beta-
cyclodextran [214]. This complex was then encapsulated into 
chitosan modified with Magnevist®, a gadolinium-based 
MRI contrast agent, to obtain theragnosis agents. Thanks to 
the anti-Aβ antibody grafted on the surface, these 
nanoparticles are capable of targeting the cerebrovascular 
amyloid deposit, and there, they were able to provide MRI 
and SPECT (single photon emission computed tomography) 
contrast and carry specific drugs to reduce de inflammation. 
The ability of the grafted nanovehicles to migrate towards 
the BBB endothelium was evaluated in vitro using a using 
quartz crystal microbalance with dissipation monitoring 
(QCM-D) technology, showing a 3-fold increase in 
comparison to the same nanoparticles without the antibody. 
Besides, they showed a higher binding and internalization to 
cells treated with Aβ, which is an indicative of their 
specificity. It was shown as well, that the antibody 
conjugated to the nanovehicles surface was important for the 
recognition and targeting of the particle, but the protonated 
chitosan chains were responsible for the internalization, as 
the antibody itself was not internalized in a high amount. 
 In a similar study conducted by Agyare et al., chitosan 
nanoparticles carrying the immunosupresant 
cyclosphosphamide, were modified with an anti-Aβ antibody 
and Magnevist® [215]. In this specific case, the antibody 
was modified with putrescine, which has been shown to 
enhance the BBB permeability of nanoparticles. These 
nanoparticles were effective in targeting cerebrovascular 
amyloid in both in vivo and in vitro studies, using human 
microvascular endothelial cell monolayer (hCMEC/D3) and 
mice respectively, and providing contrast for imaging using 
MRI and single photon emission computed tomography. The 
nanovehicles reduced the production of pro-inflammatory 
cytokines by the Aβ challenged BBB endothelium in a more 
efficient way than the drug alone, which proved their 
efficacy. It was shown that model cells where able to uptake 
in a more efficient way the antibody linked to the 
nanoparticle than the antibody itself, which shows that the 
nanovehicle, and not the antibody, plays a major role in the 
internalization. 
 It can be concluded that these nanoparticles are able to 
detect amyloid accumulation, showing good contrast for 
MRI, and treating the disease by reducing the cytokine 
secretion. Curcumin has been encapsulated using other 
strategies. Marrache et al. synthesized polymeric 
nanoparticles with varying sizes from 80 to 410 nm diameter 
and different surface charges, blending poly(D,L-lactic-co-
glycolic acid)-block (PLGA-b)-poly(ethylene glycol) (PEG)-
triphenylphosphonium (TPP) polymer (PLGA-b- PEG-TPP) 
with PLGA-COOH or PLGA-b-PEG-OH [216]. TPP is a 
single terminal lipophilic triphenylphosphonium (TPP) 
cation, which is known to cross into the mitochondrial 
matrix space. Targeted nanoparticles show greater uptake by 
the mitochondria of the treated cells that the non-targeted 
nanoparticles, proving that PLGA-b- PEG-TPP is necessary 
for the targeting action. NPs with a larger size than 200 nm, 
showed a higher immune response, which makes them 
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unsuitable for the application. The in vitro survival 
evaluation of human neuroblastoma IMR-32 cells treated 
with Aβ showed an effective neuroprotection with the 
targeted curcumin-loaded nanoparticles in comparison with 
free curcumin or non-targeted nanoparticles. 






administ. Ligand BBB 
Ligand AD 
target Drug loaded function Ref. 
Liposome 
CH, PC 180-220 i.n. - - Tacrine α-tocopherol 
Acetylcholinesterase 
inhibitor antioxidant [224] 
SPC, CH, 
DSPE-PEG 60-75 i.v. 
Peptide 
(RMP-7) - NGF Neuroprotection [223] 
DSPC, CH, 
DSPE-PEG 180-200 i.v. 
Protein 




75-170 i.v. Protein (lactoferrin) - Curcumin Neuroprotection [218] 
Nanogel 
PVP, AA 65-100 i.p. Protein (insulin) - - Neuroprotection [220] 
Polymeric 
nanosphere 
PLGA 150 i.v. Antibody (OX26Mab) - SurR9-C84A Neuroprotection [222] 
PLGA 140-170 oral Polysorbate - Estradiol Neuroprotection [219] 





PLGA-b-PEG 80-410 in vitro - TPP Curcumin Antioxidant Antiamyloid [216] 




















LEGEND. Composition. CH: cholesterol. PC: phosphatidylcholine. SPC: Soybean phospholipids. DSPE-PEG: distearoyl-N-(monomethoxy polyethylene-
glycol succinyl)phosphatidylethanolamine. DSPC: Distearoylphosphatidylcholine. CH-OA: cholesterol oleate. GLY-OA: glyceroltrioleate. S100- COOH: 
Carboxylated polyethylene glycol (100) monostearate. PVP: Poly(N-vinyl pyrrolidone). AA: Acrylic acid. PLGA: poly(lactic-co-glycolic acid). PLGA-b-
PEG: poly(D,L-lactic-co-glycolic acid)-block poly(ethylene glycol). PBCA: poly-n-butyl-cyanoacrylate. Routes of administration. i.n.:intranasal; i.p.: 
intraperitoneal. i.v.: intravenous. Ligands. RMP-7: cereport.. OX26Mab :mouse monoclonal transferrin receptor antibody. Tet-1: peptide sequence 
HLNILSTLWKYR. ApoE3: apolipoprotein E3. IgG4.1: anti-amyloid antibody, IgG4.1. IgG4.1*: F(ab′)2 fragment of anti-amyloid antibody, IgG4.1 
(pF(ab′)24.1). TPP: Triphenylphosphonium (mitochondria). Drug loaded. SurR9-C84A: mutant survivin protein. CYC: cyclophosphamide. NGF: exogenous 
nerve growth factor. 
Mathew and coworkers developed PLGA nanoparticles for 
the encapsulation of curcumin as well, but with a targeting 
moiety Tet-1 peptide [217]. This 12 amino acid peptide, that 
has similar binding characteristic to tetanus toxin, can 
interact specifically with motor neurons and is capable of 
retrograde delivery on the neuronal cells. The nanovehicles 
conserved the anti-oxidant property although they were not 
as potent as raw curcumin. It was shown that neither the 
targeted nor the non-targeted nanoparticles were toxic, but 
the uptake increased by multiple folds when they were 
targeted with Tet-1 peptide. 
Besides PLGA and chitosan based nanoparticles, curcumin 
has also been encapsulated in nanostructured lipid carriers 
based on phosphatidyl choline, cholesterol oleate and 
glycerol trioleate) [218]. A carboxylated polyethyleneglycol 
monostearate was incorporated into the formulation in 
different ratios to provide the nanoparticles surface with 
negative charge to allow the ionic adsorption of lactoferrin as 
targeting agent to the brain. The targeted delivery capacity of 
the system was proved both in vitro and in vivo experiments. 
Ex vivo imaging experiments resulted in 2.78 times more 
accumulation of lactoferrin functionalized nanoparticles in 
the brain than of non-functionalized nanoparticles. 
Histopathological studies demonstrated the efficacy of the 
system in controlling the damage associated to AD. 
Deprivation of endogenous estrogen after the menopause has 
been related as a risk factor for AD in post-menopausal 
women, and it is proven than women are two times more 
likely than men to suffer AD. Although the estrogen 
replacement therapy may reduce the risk of AD, oral 
delivery is a non-specific route that potentiates the risk of 
peripheral adverse effects, such as breast cancer. Mittal et al. 
developed tween 80 coated polylactide-co-glycolide 
nanoparticles to deliver estradiol to the brain for oral 
administration [219]. Effectiveness was evaluated in an 
ovariectomized rat model of AD to mimic the 
postmenopausal conditions. Almost a 2-fold increase in the 
levels of brain estradiol was observed with oral 
administration of tween 80 coated nanoparticles in 
comparison with uncoated. Tween 80 coated nanoparticles 
are believed to cross the BBB by endocytosis, the absorption 
to apolipoprotein E and/or B mimics a natural low-density 
lipoprotein (LDL) that can interact with the LDL receptor in 
brain capillary endothelial cells. The coated nanoparticles 
successfully prevented the expression of Aβ42 
immunoreactivity in the hippocampus region of the brain, 
indicating their potential use for oral delivery. 
Some studies have shown that insulin receptors are 
redistributed or decreased in number under Aβ stimulation, 
which relates insulin resistance and insulin action to AD. As 
it has been demonstrated recently, insulin can reduce toxicity 
induced by Aβ oligomers, as it inhibits the intrinsic apoptotic 
pathway. Besides, its activation provides neuroprotection, 
since it prevents oxidative stress, mitochondrial damage and 
neurodegeneration, so administering it to the brain could be a 
possible treatment for the disease. Insulin encapsulation is 
the safest way of administration, as systemic delivery may 
produce hypoglycemia. Poly(N-vinyl pyrrolidone)-co-acrylic 
acid nanogels (NG) were produced and insulin was grafted 
onto the surface. It is demonstrated that the grafted insulin is 
capable of activate AKT signaling and the nanogel can be 
efficiently transported to across the BBB, protecting insulin 
from protease degradation, and overall, producing a 
neuroprotective effect against the damage induce by Aβ 
[220]. 
Transferrin was very recently grafted onto liposomes amide 
coupling chemistry in order to cross the BBB. In this case, 
the cargo was alpha mangostin, a potential drug against AD 
due to its reported beneficial effect on the survival rate of 
cerebral cortical neurons against the Aβ oligomer induced 
toxicity in rats. Remarkably high encapsulation efficiencies 
of ≥88% were observed. In vitro studies with bEnd3 cells 
confirmed a preferential transport mediated by transferrin of 
the targeted liposomes, but also that clathrin might have 
participation. Consequently, in vivo studies with healthy SD 
rats showed higher accumulation of liposomes in the brain 
for the group to which transferrin grafted liposomes had 
been administered. Unfortunately no targeting efficiency was 
reported [221]. 
Sriramoju et al. used SurR9-C84A, a recombinant protein 
inhibiting apoptosis proteins, for therapy against AD. The 
activity of SurR9-C84A can be apoptotic or mitotic 
depending on the basal levels of wild-type surviving. For the 
study SurR9-C84A was encapsulated in PLGA nanoparticles 
covalently functionalized with mouse monoclonal transferrin 
receptor antibody OX26. The internalization ability of the 
targeted nanoparticles was assessed in SK-N-SH, being 
successfully uptaken within 30 min. Biodistribution studies 
also confirmed the enhanced brain specific permeation of 
anti-transferrin antibody conjugated SurR9-C84A containing 
nanoparticles which resulted a significant improvement 
against the D-Gal induced oxidative stress and in 
overcoming the behavioral compromises in the animal model 
[222]. 
A novel treatment for AD is the administration of exogenous 
nerve growth factor (NGF) to promote tropic responses in 
damaged neurons. However, NGF delivery across the BBB 
can be challenging upon intravenous administration. Xie et 
al. developed NGF loaded liposomes grafted with RMP-7, a 
ligand to the B2 receptor to cross the BBB [223]. RMP-7 
was combined with 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-n-[poly(ethyleneglycol)]-hydroxy 
succinamide (DSPE-PEG-NHS) to obtain DSPE-PEG-RMP-
7, that was then incorporated into the liposomes. The results 
showed an enhanced transport of NGF across the BBB, 
especially when RPM-7 was incorporated in the liposome, 
although NGF loaded liposomes where capable of reaching 
the brain when they were administered together with free 
RPM-7. It is believed that RMP-7 and the liposomes could 
reach the BBB at the same time, and when the BBB was 
opened, the nanoparticles could be transported into the brain. 
Finally, Corace et al. suggested a combined therapy for 
AD targeting via intranasal administration [224]. Tacrine, a 
traditional acetylcholinesterase inhibitor, was encapsulated 
in liposomes partly enriched with α-tocopherol, which 
among other benefits delivered antioxidant and 
neuroprotective effect. The liposomal formulation enhanced 
the mucoadhesion, and the permeability both across 
phospholipid vesicle-based barrier and sheep nasal mucosa. 
Furthermore, the effect of the formulation on neuronal 
viability and intracellular ROS production was evaluated as 
well as their cytoprotective effect against oxidative stress.  
CONCLUSIONS AND PERSPECTIVES 
 An increasing number of researchers are taking a 
nanotechnological approach to face the challenges posed for 
developing a therapy against AD. Nanoparticles have been 
used for extending the circulation time and stability of drugs 
already for decades.  
In recent years, nanoparticles have been applied to improve 
the permeation of drugs through the BBB, especially for 
large molecules. For this task the multivalency of 
nanoparticles has proven to be crucial, allowing for the 
functionalization of the nanoparticles with several kinds of 
targeting groups, that often are needed for penetrating the 
BBB and targeting the area of treatment. With this approach 
the most invasive administration routes would be avoided 
favoring the intravenous administration or eventually oral 
administration. Nevertheless, biodistribution studies still 
show very low targeting efficiency to the CNS and most of 
the drug and targeting agents are at the best lost and 
excreted. Yet, the low targeting efficiency is comparable to 
lower molecular weight systems. Moreover, the toxicity in 
the mid- and long-term of the nanoparticles that are to be 
administered against a chronic disease is still overlooked and 
poorly investigated. Thoroughly studies should be 
undertaken on this issue. 
 For this reason researchers are already actively 
investigating alternative routes of administration that allow 
bypassing the BBB, being intranasal drug delivery one of the 
most promising ones. In this approach, nanotechnology can 
also open new opportunities, especially with the use of 
liposomes and mucoadhesive polymeric nanoparticles. 
Reports on the bioavailability after intranasal administration 
of encapsulated drugs improve those obtained with 
intravenous administration and active targeting through 
BBB. However it is not possible to do any fair comparison 
provided the diversity of approaches (encapsulated drugs, 
nanocarrier nature) and experimental conditions. Research 
on nanocarriers for treatment of AD following intranasal 
administration is unarguably increasing and is expected to 
undergo a great acceleration in the following years. 
 During the last decades, the search for a cure of AD, also 
from the nanotechnological point of view, has been 
prominently based on amyloid cascade hypothesis, which is 
currently under question. At the moment AD is still not well 
understood and could be described as a multifactorial 
disease. For this reason combined therapies will probably be 
needed for a successful treatment. Multivalency places 
nanotechnological platforms in a good position to give 
support to this kind of approach. Several examples have been 
reported that successfully address a set of pathological 
aspects of AD. 
 Additionally multivalency opens the opportunity to a 
therasnotic approach, in which therapy will be combined 
with diagnosis in the same platform, thus allowing less 
invasive monitoring of the illness progress. 
 Nanomedicines, although far to be used as an effective 
AD treatment, are promising candidates to overcome all the 
biological barriers that make AD one of the more worrisome 
diseases nowadays. More research, combining a better 
design of “smart nanomaterials” and better in vitro and in 
vivo model systems will help to neurologists to fight against 
AD in the near future. 
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